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“There is a crack in everything. 
That´s how the light gets in.” 
 
Leonard Cohen 
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ABSTRACT 
 
Background: Infertility afflicts more than 10% of all couples worldwide. In vitro 
fertilization (IVF) is now performed at an ever increasing rate. There is scarce 
information concerning the associations between cardiovascular disease (CVD), venous 
thromboembolism (VTE) and infertility.  
 
Aims: To assess the incidence of pulmonary embolism (PE) and VTE in pregnancy 
after IVF. To investigate whether there is an association of CVD and infertility. To 
study effects of IVF on global and individual markers of haemostasis.  
 
Methods and Results: We studied all women who had given birth to a child after IVF 
(n=23,498) between 1990 and 2008 and individually matched women by age and 
calendar year (n=116,960). Information from the Swedish Medical Birth Register was 
linked to the Swedish National Patient Register in a cross-sectional study. The 
incidence of VTE was found to be increased during all pregnancy after IVF compared 
to pregnancy after natural conception. During the first trimester the risk was increased 
fourfold for VTE and sevenfold for PE.  
We also studied the two groups after delivery until occurrence of hypertension, stroke, 
coronary heart disease, diabetes mellitus or until end of follow-up (average follow-up 
time eight years). Both univariable and multivariable analyses showed a higher 
incidence of hypertension after IVF pregnancy compared to control. There was a 
tendency towards a higher incidence of stroke, whereas the incidence of coronary heart 
disease and diabetes did not differ. 
Furthermore we studied 31 women undergoing IVF at maximal downregulation (DR) 
and during high-level stimulation (HLS) of oestradiol synthesis. Antigen levels and 
activities of both von Willebrand factor (VWF) and ADAMTS13 in plasma were 
determined at DR and at HLS. Haemostasis was also assessed with 1) the calibrated 
automated thrombogram (CAT; measures thrombin generation), 2) overall haemostasis 
potential (OHP; measures fibrin formation and degradation) and 3) fibrin gel 
permeability measurements (assesses fibrin network characteristics). The increments in 
oestradiol during IVF were paralleled by an increase in VWF antigen and activity 
respectively a decrease in circulating ADAMTS13 antigen and activity. We found both 
an increased thrombin generation and fibrin formation from DR to HLS, whereas fibrin 
gel permeability did not change.  
Conclusion: IVF pregnancy is associated with an increased risk of PE and VTE, in 
particular during the first trimester. The risk of PE is low in absolute terms but because 
the condition is a leading cause of maternal mortality and clinical suspicion is critical 
for diagnosis, an awareness of this risk is important. The mechanistic studies identified 
procoagulable changes in haemostasis during the IVF procedure.  
Hypertension was more prevalent after IVF pregnancy. This association of CVD and 
infertility suggests that infertility and CVD could share common pathophysiological 
mechanisms.  
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1 BACKGROUND 
1.1 VENOUS THROMBOEMBOLISM (VTE) 
In the blood stream there should under normal conditions be a balance between blood 
clotting and lysis of blood clots. Imbalance between these entities can result in 
thrombosis or bleeding. Rudolf Virchow’s triad from 1856 still remains true 1. It states 
that 1) alterations in the vessel wall, 2) disturbances in blood flow or 3) disturbances in 
the constitution of blood are present in thrombosis. 
Two major clinical manifestations of thrombosis on the venous side are deep venous 
thrombosis (DVT) and pulmonary embolism (PE). These conditions are collectively 
called venous thromboembolism (VTE). 
There are several risk factors for VTE and many of them mechanistically belong to one 
of the “factors” identified by Virchow. Examples of risk factors are surgery, 
malignancy, immobilization, pregnancy, oestrogen treatment and thrombophilia (any 
coagulation disorder associated with increased tendency to VTE). Inherited 
thrombophilia includes activated protein C (APC) resistance (Factor V Leiden 
mutation), prothrombin mutation or deficiencies of either antithrombin (AT), protein S 
or protein C. The most common forms of acquired thrombophilia are phospholipid 
antibodies (lupus anticoagulant or cardiolipin antibodies) and acquired APC resistance.  
In addition, smoking, high levels of FVIII and previous venous thrombosis increase the 
VTE risk 2-4. 
It still remains controversial whether atherosclerosis and cardiovascular disease (CVD) 
risk factors are associated with risk of VTE 5. Patients with unprovoked VTE were, 
however, recently reported to have an increased incidence of CVD 6 and an association 
between atherosclerotic disease and spontaneous VTE has also been observed 7. 
Furthermore, the fact that the statin rosuvastatin significantly reduced the occurrence of 
symptomatic VTE in apparently healthy persons could favour such a contention 8. 
 
1.1.1 Risk of VTE in fertile women 
The risk for a healthy fertile woman to suffer from VTE is fortunately low. The 
observed incidence of VTE in a population-based study in Sweden was 0.11, 0.26 and 
0.97 per 1000 women at the ages 20-29, 30-39 and 40-49 years, respectively 9. 
Since the oral contraceptives (OC) were introduced in the 1960s and the awareness that 
exogenous oestrogens are associated with VTE, the risk of VTE among OC users has 
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been extensively studied. Thus, OC with low oestrogen content seems to cause less 
VTE compared with OC with high oestrogen contents 10, 11. However, the absolute risk 
of VTE associated with OC use is lower (one in 3000 to 5000) than the risk of 
pregnancy-associated VTE 12.  
 
1.1.2 Risk of VTE during pregnancy 
VTE is one of the leading causes of maternal death in the industrialized countries with 
an incidence of 1.1 per 100.000 deliveries 13. The risk of VTE is approximately 5-fold 
increased during normal pregnancy, especially during the third trimester and in the 
postpartum period (six weeks after delivery) 14. One pregnant woman out of 1000 
suffers from VTE according to data from Sweden and Norway 15, 16.  
The increased risk of VTE during pregnancy is most likely due to several factors, many 
of them directly related to haemostasis. These include gradually increasing plasma 
levels of coagulation factors and von Willebrand factor (VWF) 17, 18 as well as 
decreasing levels of natural anticoagulants 19, altogether causing a procoagulable state. 
Furthermore, fibrinolysis is depressed as circulating levels of plasminogen activator 
inhibitor-1 and -2 (PAI-1 and PAI-2) are elevated and plasma levels of tissue type 
plasminogen activator (tPA) are reduced 20, 21. This shift in haemostasis towards a 
procoagulant state is of course important for minimizing blood loss during delivery, but 
unfortunately it also contributes to an increased VTE risk during pregnancy 22. Of note, 
inherited and acquired thrombophilia increase the risk of VTE during pregnancy even 
further 23. Alterations in blood flow during pregnancy may also contribute to an 
increased risk of VTE. Stasis of blood flow in the left iliac vein due to pressure from 
the right iliac artery causes an overrepresentation of DVT in the iliofemoral veins of the 
left leg 17. Another contributing cause of VTE during pregnancy is the 50% reduced 
venous flow velocity in the legs during the third trimester 24. 
The more common proximal localization of the thrombosis during pregnancy and its 
association with more unspecific symptoms clearly constitute diagnostic and 
therapeutic challenges. See table 1 below for further data on effects of pregnancy and 
OC on various aspects of haemostasis. 
 
1.1.3 Risk of VTE during in vitro fertilization  
Occurrence of VTE during in vitro fertilization (IVF) pregnancies has been reported in 
several case reports and two small consecutive series [two out of 2500 (0.8/1000 
respectively three out of 2748 (1.1/1000)] 25, 26. However, the incidence estimates of 
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Table 1. Different effects of in vitro fertilization (IVF), pregnancy, oral contraceptives 
(OC) and hormone replacement therapy (HRT) on haemostasis. 
 
  IVF Pregnancy OC  HRT 
Coagulation  Fibrinogen 27 28 
 
29 
  
30, 31 
factors FII 32 33 
 
29    
 FV 32 33 
 
29 34 
 FVII 35 28 
 
36 31 
 FVIII 35 28 
    
29, 37 38 
 FIX 32 33  
 
39 31 
 FX    28 
 
36 30 
 FXI    40 
 
41 42 
 FXII 43 40 
 
44 30 
 FXIII   28 
 
45    
Coagulation  AT 27 28  
46 47 
inhibitors Heparin cofactor 2 48 
 
49, 50 
 
49    
 Protein S  35, 48 51 
 
46 31 
 Protein C 35 51 
 
46 47 
 APC resistance 52 53 
 
54 55 
 TFPI 66 50 
 
67 65 
Fibrinolysis t PA 48, 56 51 
 
57 31 
 PAI-1 48, 56 51 
 
58 59 
 PAI-2    60       
 Plasminogen 48 61 
 
57 47 
 α²-antiplasmin 48 40    47 
 TAFI 62 63 
 
64 65 
 PAP complex 68 69 
 
70 71 
Global  TEG  72 73 
  
74, 75    
methods OHP 76 77       
 TGA 76 78 
 
79 80 
 Fibrin gel       76          
Platelets Aggregation 81 
 
82 83 84 
Micro- 
particles 
 Platelet MP    
 
85    
 
86 
 Endothelial MP    85    86 
Miscellaneous PT (INR) 32 51  
37 47 
 PTT 32 51 
 
37 31 
 D-dimer 35 60 
 
70 31, 87 
 Soluble fibrin 35 60 29 87 
 F 1+2 48 51 
 
29 88 
 TAT complex 48, 56 89 29 90 
 VWF 35 28 37 38 
  ADAMTS13 91 92 
 
93    
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Interestingly, VTE during IVF has been reported to be predominantly located in the 
upper extremities and jugular veins 25. There are different hypotheses behind this 
finding. One is that the high oestradiol concentration in the lymphatic fluid of the 
thoracic duct causes a local inflammation in the veins which in turn precipitates 
thrombus formation 94. 
There is little information available about the risk profile of PE following IVF. Indeed, 
this is an important issue since PE is a potentially lethal condition 95, 96. 
 
1.2 IN VITRO FERTILIZATION 
IVF is the most common procedure performed to assist reproduction. Since the first 
attempt in 1978 IVF treatment has been used at an increased frequency 97, resulting in 
the birth of approximately five million “test tube babies” worldwide. The IVF 
procedure is regarded both effective and safe with about 30% of the attempts resulting 
in a pregnancy and 25% in a live birth 98, 99. 
Gonadotropin-releasing hormone (GnRH) agonists and follicle-stimulating hormone 
(FSH) are administered during the IVF pretreatment, causing a rapid increase in 
circulating oestradiol levels from very low concentrations during the down-regulation 
phase (GnRH) to supraphysiological concentrations during the stimulation phase 
(FSH). This results in the production of multiple ovarian follicles. Notably, the 
maximal oestradiol levels during IVF are usually equal to or sometimes even exceeding 
late pregnancy oestradiol concentrations 100 (figure 1). 
Several studies demonstrate that the rapid increase in oestradiol levels in plasma 
attained during IVF may induce a procoagulable state through direct effects on several 
haemostatic variables as shown in table 1. Indeed, IVF pretreatment is a unique model 
to study short-term effects of endogenous oestrogens on haemostasis. 
A major complication of IVF is the ovarian hyperstimulation syndrome (OHSS), 
characterized by ovarian enlargement and fluid shift to the third space due to capillary 
leakage 101. Depending on the severity of OHSS, its incidence rate has been described 
to vary between 0.5% and 23% 102, 103. Severe cases are associated with arterial and 
venous thrombotic complications 104, but because of lack of a systematic registration 
there are no existing precise figures of incidence rates of thrombotic complications. 
High serum oestradiol concentrations, increased number of small ovarian follicles at the 
time of ovulation induction, polycystic ovarian syndrome (PCOS), young age and a low 
BMI are factors known to relate to the development of OHSS 105. The predictive value 
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of any of these factors for the development of OHSS is not high, and there are 
conflicting reports in the literature on the relation of these variables to OHSS 106, 107. 
 
1.3 OESTROGEN 
Oestrogen is the main female sex hormone and essential for menstruation and 
reproduction. The three major naturally occurring oestrogens in women are oestrone 
(E1), oestradiol (E2), and oestriol (E3). Oestradiol, which is the predominant oestrogen 
during reproductive years, reaches the highest levels in plasma and has the greatest 
oestrogenic activity. Luteinizing hormone (LH) from the pituitary gland stimulates the 
oestrogen production in the ovaries, while increase of follicle-stimulating hormone 
(FSH) from the pituitary gland causes ovulation. For reproduction these two hormones 
have to act synergistically. Progesterone, the major progestogen, is involved in the 
menstrual cycle and supports gestation and embryogenesis. 
During the fertile period of a woman’s life, almost all biologically active oestradiol is 
secreted from the developing follicles in the ovaries and during pregnancy even from 
the placenta. The plasma level of oestradiol varies during the menstrual cycle, with the 
lowest levels in the early follicular phase and the highest levels at the time of ovulation. 
The majority of oestrogen (40-90%) is bound to a carrier protein in the blood, sex 
hormone-binding globulin, which is produced in the liver. About 10-30% of oestrogen 
in plasma is bound to circulating albumin, and only about 1% remains as a free fraction 
exerting biological effects. There is also some production of oestrogen in the liver, 
adrenal glands, breasts and fat cells, the latter potentially being the reason why 
underweight or overweight are risk factors for infertility 108.  
 
1.4 CARDIOVASCULAR DISEASE 
1.4.1 Infertility and cardiovascular disease 
In women, heart disease is the leading cause of death while stroke is the third most 
common cause of death 109. Infertility afflicts more than 10% of all couples worldwide 
110 and the cause of infertility is usually divided into female factors, male factors and 
unknown factors. Both obesity as well as underweight seems to be associated with 
reduced fertility in women 111. In addition, smoking, increasing age and environmental 
factors seem to impair development and function of the reproductive organs, which 
could lead to hormonal imbalance and fertility problems in both men and women 112. 
The most common cause of female infertility is the polycystic ovarian syndrome 
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(PCOS) 113, 114. Interestingly, women with PCOS have a sevenfold increased risk of 
myocardial infarction 115. Endothelial dysfunction is an early marker of CVD 116 and 
has been found in women with PCOS as well as in animal models of this condition 117, 
118. Possible associations between endothelial dysfunction in the ovarian vasculature 
and infertility have, however, to our knowledge not yet been studied. In addition, 
women with PCOS have menstrual irregularities, which have also been associated with 
subfertility 119 and an increased risk of CVD 120.  
 
1.4.2 Hormone replacement therapy and cardiovascular disease 
There are a lot of conflicting reports regarding hormone replacement therapy (HRT) 
and CVD risk. Some register studies suggested that HRT reduced the risk of coronary 
heart disease 121, whereas randomized double blind trials [Heart and Estrogen/progestin 
Replacement Study (HERS) and Women’s Health Initiative (WHI)] suggested that 
HRT on the contrary increase the risk of VTE and coronary heart disease 122, 123. 
 
1.5 HAEMOSTASIS 
A well balanced haemostatic system is necessary to prevent thrombosis or bleeding. 
Haemostasis includes the “clotting process” from the formation of platelet plugs and 
clots to lysis of the clot, and is traditionally divided into primary and secondary 
haemostasis (figure 2).  
 
Figure 2. Schematic summary of haemostasis.  
 
 
 
There are many important components involved in the haemostatic process, including 
vessel wall, platelets (Plt), white blood cells, coagulation factors and inhibitors, 
fibrinolytic factors and inhibitors, calcium ions, phospholipids as well as the blood flow 
124, 125. Most interactions between the factors of the haemostatic system occur on 
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surfaces, i.e. on surfaces of activated cells (e.g. platelets or endothelial cells), on 
microparticles released from cells, or on collagen exposed in the injured vessel wall 126. 
In fact, a “cell-based model of coagulation” is used nowadays. This view is probably 
the most accurate as it involves not only the plasma factors but also the complex 
interactions between cellular components and plasma factors (see figure 3 and text 
below). However, blood coagulation has traditionally been described as a cascade of 
distinct enzymatic reactions where proteolytic activation of a proenzyme leads to 
activation of the next proenzyme 126, and this view has still some value in terms of 
understanding of this very complex system. The coagulation proenzymes or cofactors 
are either vitamin K-dependent (FII, FVII, FIX and FX) or thrombin-dependent 
(fibrinogen, FV, FVIII, FXI and FXIII).  
Coagulation is tightly controlled and sequences of interactions result in the formation of 
thrombin and subsequently fibrin. A series of events that comprise a sequence of 
proteolytic cleavages at very specific sites on the proenzymes or cofactors occur. These 
activation steps cause conformal changes of the proteins, which in turn expose their 
enzymatically active sites and/or binding sites for cofactors, phospholipids and other 
specific receptors located on various cell surfaces 125. In some situations, the precursor 
protein can be activated not only by coagulation factors but also by other proteases, for 
example enzymes from tumour cells, microorganisms and white blood cells or proteins 
released from surfaces that have become exposed due to vessel damage. 
 
Figure 3. Cell-based coagulation. 
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1.5.1 The coagulation process 
The cell-based model has three distinct but overlapping steps; the initiation, the 
amplification and the propagation phases 127. A schematic presentation of the three 
steps in coagulation is shown in figure 3. 
 
1.5.1.1 The initiation of blood coagulation 
During the initiation phase of haemostasis, the damage to the vessel wall brings plasma 
into contact with cells bearing tissue factor (TF). A small amount of circulating 
coagulation factor VII (FVII) binds to TF and is rapidly activated. The FVIIa/TF 
complex, together with the cofactors Ca2+ and phospholipids exposed on activated cells 
or microparticles, activates more FVII but also FX and FIX. FIXa, in turn, forms a 
complex with FV on TF-bearing cells, and together the two activated proteins produce 
small amounts of thrombin. Depending on the strength of the stimuli, the initiating 
process will either proceed or will be stopped through the action of inhibiting factors 
such as tissue factor pathway inhibitor (TFPI). 
 
1.5.1.2 The amplification of blood coagulation 
In the amplification phase, small amounts of initially generated thrombin activate 
circulating platelets, enabling platelets to adhere to the site of injury. Platelet adhesion 
to subendothelial surfaces is mediated by VWF, which acts like a glue between 
platelets and collagen. Circulating VWF/FVIII complexes bind to activated platelets 
and more FVIII is released and activated by thrombin. Thrombin-induced platelet 
activation also results in release and activation of FV from the platelets.  
 
1.5.1.3 The propagation of blood coagulation 
The last phase includes formation of procoagulant complexes on platelets and 
microparticle phospholipid surfaces. The tenase complex (FIXa/FVIIIa) activates FX, 
which in turn forms the prothrombinase (FXa/FVa) complex and induces a thrombin 
burst. The cleavage of prothrombin into thrombin occurs through several steps, 
producing the active enzyme alpha-thrombin and prothrombin fragment 1+2 (F1+2). 
Thrombin converts fibrinogen to fibrin in the last step of the coagulation cascade, and 
the fibrin fibrils are cross-linked by Factor XIII into an insoluble fibrin network which 
stabilizes the platelet plug. 
Strict regulation of the coagulation process and activation only at a local site of injury is 
essential to avoid massive systemic fibrin deposition. The regulation of this process is 
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very complex, with strong negative and positive feedback systems. The most important 
positive feedback is considered to be activation of FV by thrombin, while various 
anticoagulant proteins and cofactors also contribute and act as important inhibitors of 
this system. 
 
1.5.2 Contact pathway 
The contact pathway starts with the activation of FXII from either collagen or 
polyphosphates secreted from platelets. FXIIa starts the cascade by activating FXI, 
which subsequently activates FIX. The contact pathway then merges into the initiation 
phase of the cell-based model as FIXa activates FX. The contact pathway is an 
interesting target for future antithrombotic treatment as animal models have shown that 
FXII deficient mice have a normal haemostatic capacity but a defect thrombus 
formation protecting them against both venous and arterial thromboses 128. 
 
1.5.3 Coagulation inhibitors 
The coagulation inhibitors balance the reactions in the coagulation process. Tissue 
factor pathway inhibitor (TFPI) inhibits both the produced FXa and the FVIIa/TF 
complex during the initiation phase. Antithrombin (AT) is the main inhibitor of 
thrombin and binds irreversibly to its target forming the thrombin-antithrombin 
complex (TAT). AT also inactivates FIXa, FXa, FXIa and FXIIa. Heparin used in 
anticoagulant therapy binds to AT causing a conformational change that leads to 
activation of the protein 129. 
After binding to thrombomodulin on the surface of endothelial cells, thrombin initiates 
the anticoagulant pathway by activating protein C. Activated protein C (APC) together 
with Protein S as cofactor inhibits thrombin formation through proteolytical 
inactivation of FVa and FVIIIa 130.  
 
1.5.4 APC resistance 
APC resistance is a decreased response to the anticoagulant function of APC and an 
important risk factor for the development of VTE 131. This resistance can also be 
acquired in some conditions such as IVF 52, pregnancy 53 and use of oral contraceptives 
54 and is associated with increased thrombin generation 132. 
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1.5.5 Fibrinogen 
Fibrinogen is a soluble glycoprotein, which is synthesized in the liver. Approximately 
75% of total fibrinogen is present in plasma 133 and under normal conditions at a 
concentration of 2-4 g/L. The rest is distributed in interstitial fluid and in the lymph. 
Fibrinogen is an important regulator of thrombin activity in clotting blood and the 
fibrinogen plasma level is an independent risk factor for both arterial and venous 
thrombosis 134. Plasma fibrinogen is the “substrate” of the fibrin network and influences 
the structure of the fibrin network, as tighter networks are formed in the presence of 
higher fibrinogen levels 135, 136. 
 
1.5.6 Fibrinolysis 
The fibrinolytic system dissolves and removes blood clots from the circulation. tPA is 
the main regulator of fibrinolysis, cleaving plasminogen into plasmin. Plasmin in turn 
cleaves fibrin into degradation products, i.e. d-dimers. The main inhibitors of 
fibrinolysis are PAI-1 and PAI-2 (which inhibit tPA) and α2-antiplasmin (which 
inhibits plasmin). PAI-2 is produced only by the placenta of pregnant women and its 
plasma level increases with gestational age 137. 
 
1.5.7  Endothelial related factors 
1.5.7.1 Von Willebrand factor 
Von Willebrand factor (VWF), formerly called factor VIII-related antigen, is an 
adhesive plasma glycoprotein synthesized in endothelial cells and megakaryocytes. It 
plays a major role in primary haemostasis by serving as a link between platelets and the 
damaged vessel wall, and indirectly contributes to coagulation by binding, stabilizing 
and protecting circulating FVIII from degradation 138. VWF is stored in Weibel-Palade 
bodies in endothelial cells and in α-granules of platelets. In response to vascular 
damage, the rapid release of ultra-large VWF multimers mediates platelet adhesion. 
VWF multimers circulate in a “folded” inactive form 139, but under shear stress the 
molecule exposes its binding sites in the stretched and unfolded form 140. 
Endothelial dysfunction is associated with increased circulating levels of VWF in both 
arterial and venous vessels 3, 141, 142. During pregnancy, both VWF and FVIII levels 
raise two- to threefold during the second and third trimesters 28, 40, and increased VWF 
and FVIII levels are also seen during IVF treatment 35, 143. Interestingly, high plasma 
levels of VWF are associated with severe OHSS. It has been argued that assessment of 
VWF may be of value in predicting OHSS 144.  
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1.5.7.2 ADAMTS13 
An important regulatory mechanism of VWF levels in plasma is the activity of a zinc-
containing metalloprotease enzyme, ADAMTS13 (a disintegrin-like and 
metalloprotease with thrombospondin type I motifs), also known as VWF-cleaving 
protease. As shown in figure 4, this enzyme cleaves the unfolded VWF at a single site 
in the A2 domain, thereby converting ultra-large VWF multimers into lower molecular 
weight forms with reduced adhesive potential 145, 146.  
 
Figure 4. Possible sites of ADAMTS13 action on VWF.  
 
 
From Sadler et al. with permissions from publisher 147. Copyright 2013 National 
Academy of Sciences, U.S.A. 
 
There is a negative association between plasma levels of VWF and the activity of 
ADAMTS13. The latter tends to be low in plasma when VWF is high 148-150. 
ADAMTS13 appears to be produced in the liver, but reports also indicate platelets and 
endothelium as production sites 151, 152. Thrombin and plasmin can inactivate 
ADAMTS13 by cleavage and thereby regulate its activity at the site of thrombus 
formation 153. Interestingly, patients with thrombotic microangiopathies like thrombotic 
thrombocytopenic purpura have a reduced function of ADAMTS13 154-156, and 
ADAMTS13 is therefore a target for diagnosis and treatment of this serious disease 157. 
There are some studies indicating a moderate decrease of this protease during 
pregnancy and puerperium 158. However, ADAMTS13 has not been investigated 
previously in patients undergoing IVF.  
Immunologic assays can measure ADAMTS13 antigen concentrations, but measuring 
the activity of the enzyme is associated with methodological difficulties. Kokame et al. 
 19 
 
have developed a new method which involves the use of a small fluorogenic labelled 
substrate for ADAMTS13 called FRETS-VWF73 155. This substrate is a VWF 
fragment consisting of 73 amino acids. The method is commercially available, easy to 
perform, has a high specificity for ADAMTS13 and is able to detect decreased activity 
due to different causes. 
 
1.5.8 Global markers of coagulation 
Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are the two 
routine assays for coagulation screening with a detectable clot as end point. The use of 
aPTT and PT in detecting prothrombotic states and in the monitoring of new 
antithrombotic agents is not optimal 159. These methods are based on the formation of a 
detectable fibrin clot, which occurs already when 3-5% of the total amount of thrombin 
is produced. Haemostatic reactions occurring later on in the process may thus not be 
detected. 
From a clinical point of view it is better to have functional methods as general 
indicators of coagulability. Ideally, such methods could be used to assess the balance 
between coagulation and fibrinolysis in the patient´s plasma. 
Very little is known about the haemostatic balance during IVF treatment. Although 
there is a wide spectrum of recently developed global haemostatic assays, only 
thromboelastography (TEG) has, to our knowledge, so far been used to assess changes 
during IVF 72. TEG is a global method performed in whole blood and carried out 
bedside. It monitors clot formation as well as clot stability and dissolution 160. An 
advantage with this method is the possibility to study interactions between blood cells, 
platelets and plasma constituents, but the test has to be performed within a few hours 
after blood sampling which limits its use in larger clinical studies. 
 
1.5.8.1 Calibrated Automated Thrombogram  
Calibrated Automated Thrombogram (CAT) is another commercially available global 
haemostatic method. By using tissue factor (TF) as a trigger, the thrombin generation 
potential of the patient’s plasma is assessed, forming a temporal curve of the total 
thrombin generation. The area under the curve is called the endogenous thrombin 
potential (ETP) 161. The CAT assay is based on the assumption that thrombin 
generation in examined plasma reflects the sum of the activities and concentrations of 
pro- and anticoagulant substances. The investigated variables include ETP and related 
parameters, namely lag time (i.e. time to start of detectable thrombin formation), peak 
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height (i.e. maximal thrombin concentration attained) and time to peak (i.e. the time 
taken to obtain peak height).  
Increasing evidence shows that CAT may be a useful assay both in the diagnosis of 
procoagulable states and in the detection of certain bleeding disorders 162, 163. Patients 
with thrombotic disorders, e.g. DVT and stroke, have higher ETP 164, 165. CAT may 
provide additional information beyond what is obtained through measurements of 
traditional markers of thrombin generation, such as F1+2 or TAT. As stated by Al 
Dieri, Laat and Hemker: thrombin generation as assessed by ETP “indicates a fire 
hazard, while F1+2 and TAT are smoke detectors” 166. 
However, even though this method gives information about the coagulation capacity in 
plasma through assessment of thrombin generation, it does not measure the final step of 
coagulation, i.e. fibrin formation. Furthermore, fibrin degradation, i.e. fibrinolysis, is 
not assessed.  
 
1.5.8.2 Overall Haemostasis Potential  
He & Blombäck developed the Overall Haemostasis Potential (OHP) assay as a 
quantitative method for determination of the fibrin formation and degradation in plasma 
167. Spectrophotometric measurements reflect the fibrin fibril formation through 
changes in turbidity during the test period of 40 minutes. Previous investigations have 
shown that this approach can be used to detect a variety of procoagulable 167-169 as well 
as hypocoagulable disorders 169, 170.  
Fibrinogen and FVIII are increased during IVF 35, 48 and seem to correlate to the 
variables of the above mentioned global haemostasis assays 161, 167 which supported 
their assessment in study II.  
The clot lysis time (CLT) may be viewed upon as a global assay of fibrinolysis in 
which triggers of both coagulation (TF, phospholipids and calcium) and fibrinolysis 
(recombinant tPA) are added to plasma. The changes in absorbance attained are 
measured during clot formation and lysis. We performed the CLT assay as another part 
of the OHP assay. 
 
1.5.8.3 Fibrin network 
To study the characteristics of the fibrin network, we used the liquid-permeation 
technique which investigates the permeability of a fibrin gel formed after addition of 
thrombin (or TF) to a plasma sample 171, 172. The test thus provides information about 
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fibrin network characteristics including the fibre mass/length ratio and the 
permeability coefficient of the fibrin gel in vitro 171, 173. The permeability coefficient 
(Ks) is an established variable that provides information on the network structure and 
reflects the size and shape of the pores in the fibrin gel formed. Collet et al. studied 
the fibrin network by using real-time confocal microscopy techniques in vitro, 
demonstrating that a tight fibrin network formation with smaller pores was more 
difficult to lyse 174. Low values of Ks indicate a tighter, less porous fibrin network, 
which is more resistant to fibrinolysis 173 and may be associated with thrombotic 
complications 175. 
Patients with diabetes, stroke and VTE have tighter fibrin networks 176-178. However, as 
of today there are no large prospective clinical trials studying fibrin network structure 
and its relationship to future thrombotic complications. 
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2 AIMS 
 
• To evaluate the effects of IVF on haemostasis.  
 
• To assess the incidence of pulmonary embolism and venous 
thromboembolism in pregnant women after IVF. 
 
• To estimate whether cardiovascular disease and some related risk factors have 
a higher incidence in women after IVF pregnancy as compared to women who 
delivered after natural conception.  
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3 MATERIAL AND METHODS 
3.1 PATIENTS 
3.1.1 Studies I-II 
We investigated plasma samples of 31 consecutive women undergoing IVF treatment 
at the Fertility Unit of Karolinska University Hospital, Huddinge, during 2006-2008. 
Upon inclusion, patients were interviewed regarding smoking habits, ongoing 
medication and own or family history of VTE, diabetes mellitus and CVD. Patients 
with polycystic ovarian syndrome (PCOS) or ongoing anticoagulation treatment were 
excluded.  
 
3.1.2 Studies III-IV 
IVF group (exposed women) consisted of 23,498 Swedish mothers who had their first 
child born as a result of IVF during 1990-2008 and were retrieved from the Swedish 
IVF Register at the National Board of Health and Welfare.  
A control group (unexposed women) was retrieved from the Medical Birth Register 
(MBR). Each IVF woman was matched with five unexposed women from this register 
by calendar year of delivery ±2 years and maternal age ±1 year. This resulted in 
116,960 unexposed women. 
For all women we also retrieved information on their country of birth, pre-pregnancy 
body mass index, family situation, cigarette smoking habits, singleton/multiple births, 
and estimated length of gestation from MBR. Trimester dates were calculated from 
length of gestation.  
Follow-up in study IV started at the time of delivery. End of follow-up was 31st of 
December 2009 or the date of first registered event of one of the following: a CVD 
diagnosis (coronary heart disease or stroke), a diagnosis of a related risk factor 
(hypertension or diabetes), emigration from Sweden or death. 
 
3.2 BLOOD SAMPLING 
In study I and II venous blood sampling was always performed under fasting 
conditions, through direct venipuncture and after a 20 minutes supine rest. 
Blood was drawn into vacuum tubes containing trisodium citrate (0.13 mol/L, pH 7.4). 
The tubes were immediately centrifuged for 20 minutes (2000g, room temperature), 
and platelet-poor plasma aliquots were stored at -80°C. 
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We performed two blood samplings during the IVF procedure: the first at time of 
maximal down-regulation (DR) of oestradiol synthesis (<150 pg/mL) and the second at 
time of high level stimulation (HLS) of oestradiol synthesis preceding human chorionic 
gonadotropin (hCG) administration (7-10 days after the first blood test).  
During the first blood sampling, the following routine blood tests were performed: 
haemoglobin, platelet count, white blood cell count, haematocrit, creatinine, sodium, 
potassium, plasma glucose and C-reactive protein (CRP).  
 
3.3 IN VITRO FERTILIZATION 
The IVF procedure is illustrated in figure 5. To induce controlled ovarian hyper-
stimulation, the oestrogen production was first down-regulated by using a GnRH 
agonist administered as a nasal spray and starting on the 21st day of menstrual cycle. 
After the menstrual bleeding, two weeks later, an oestradiol measurement was carried 
out to verify down-regulation. Acceptable baseline oestradiol concentration for 
initiating the IVF cycle was <150 pg/ml. After that, the GnRH dose was decreased. 
 
Figure 5. The IVF procedure. 
 
 
The ovarian stimulation was then initiated by using recombinant human FSH 
administrated subcutaneously. The response was followed up by an oestradiol 
measurement six days later, and by ultrasound scanning of the ovarian follicles at days 
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9-10 after the first FSH injection. The oestradiol measurement and ultrasound scanning 
were repeated when necessary. 
Transvaginal ultrasound-guided oocyte retrieval was planned when the largest follicles 
had reached a diameter of 18 mm. At that stage, recombinant or urine-purified hCG 
were given to induce the final maturation of the oocytes, which were retrieved 36-38 
hours later. Thus, oocytes were retrieved 10 to 14 days after starting FSH stimulation. 
The embryo transfer procedure was carried out three to five days after oocyte retrieval. 
In order to improve fertility outcome the women were given progesterone vaginally 
during the first weeks after embryo transfer.  
 
3.4 GLOBAL HAEMOSTASIS ASSAYS 
3.4.1 Calibrated Automated Thrombogram  
The analysis was performed at the Clinical Research Center at Danderyd Hospital. We 
used the method described by Hemker et al. 161 and according to the manual provided 
by Thrombinoscope BV (Maastricht, the Netherlands). Briefly, we triggered 
coagulation in platelet-poor plasma by adding a reagent giving final concentrations of 5 
pM TF and 4 µM phospholipids. Fluorescence was measured at 390/460 nm every 30 
seconds over a period of 40 minutes. Both calibrator and thrombin generation were 
analyzed in triplicate using commercially available ThrombinoscopeTM software, and 
we calculated both mean levels and standard deviation. We derived the following 
variables from the thrombin generation curves: lag time (initiation phase, time to reach 
one-sixth of the peak height), ETP (total amount of thrombin formation over time 
which is measured as area under the curve), peak height (i.e. peak thrombin 
concentration attained) and time to peak (i.e. time to peak thrombin concentration), as 
shown in figure 6. The CAT assay is convenient to perform and it takes only one hour 
to run 16 samples in a microplate. The method has acceptable reproducibility, with an 
inter-assay coefficient of variation (CV) less than 5%.  
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Figure 6. A typical thrombin generation curve showing the main variables of the 
thrombogram. 
 
 
Obtained with permissions from Haematologica/the Hematology Journal website 
http://www.haematologica.org 179. 
 
Thrombin generation was measured in each plasma sample in both the presence and 
absence of 4.8 nM/mL APC. This is the concentration of APC sufficient to obtain an 
80-90% decrease in ETP. The ETP-based APC sensitivity ratio (APCsr) is defined as 
the ETP in the presence of APC divided by the ETP in the absence of APC. To reduce 
variation between assays, results are expressed as normalized APCsr by dividing the 
APCsr of the sample by the APCsr of pooled normal plasma 180 as described below: 
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3.4.2 Overall Haemostasis Potential  
In Study II we used the Overall Haemostasis Potential (OHP) assay described by He et 
al. This is a functional method which assesses both fibrin formation and lysis 77. The 
OHP curve is an absorbance curve formed by repeated spectrophotometric registration 
of fibrin fibril formation after adding triggers of coagulation (calcium and thrombin) 
and fibrinolysis (recombinant tPA) to citrated plasma in the well.  
The OHP curve forms when both triggers of coagulation and fibrinolysis are present in 
the sample. The Overall Coagulation Potential (OCP) forms when only triggers of 
coagulation are present. 
Absorbance (Abs) at 405 nm was measured every minute for 40 minutes to construct 
the two fibrin aggregation curves (OCP and OHP). The area under the curve was 
expressed by a summation of the Abs values (Abs-sum). The difference between the 
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In brief, a 10 µl TRIS buffer containing 0.42 mol/l CaCl2 and 8.3 IU/ml thrombin, 
giving final concentrations of 20 mmol/l and 0.4 IU/ml, respectively, was added to 200 
µL dialyzed plasma in a small plastic cylinder (2.5 cm long, opening area 0.1 cm2). The 
fibrin gel cylinder was kept in a standing position in a wet box at room temperature 
overnight.  
Permeability (porosity) measurements of the gel were carried out through 
measurements of the volume of a buffer (pH 7.4, 0.02 mol/L TRIS, 0.02 mol/L 
imidazol, 0.1 mol/L NaCl) percolated through the gel under different hydrostatic 
pressures. The permeability coefficient (Ks) was calculated using the equation by Carr 
et al. from 1977 184. The method is both labour and time consuming and it takes one 
working day to analyze 8-10 samples. The method is described in detail in Paper II. 
 
3.5 ENDOTHELIAL RELATED FACTORS 
3.5.1 Von Willebrand factor 
VWF antigen was measured in plasma using the LIATEST from Diagnostica Stago 
(Asnieres, France) and assayed using BCS equipment (Dade Behring, Marburg, 
Germany) at the Clinical chemistry laboratory of Karolinska University Hospital, 
Solna. The measurement procedure was performed according to the manufacturer’s 
instructions 185, 186. Thus, latex particles covered with antibodies against VWF are 
mixed with the sample building a complex consisting of antigen (VWF) and antibody 
latex particle. A monochromatic light with the wavelength 570 nm is sent through the 
suspension. If there is much antigen in the sample, there will also be more complexes 
resulting in more absorption of light. The increased speed of the light absorption is 
direct proportional to the VWF concentration in plasma.  
VWF activity was assayed as ristocetin cofactor activity in plasma using the BC von 
Willebrand Reagent from Siemens Healthcare Diagnostics (Deerfield, ILL, USA) at the 
Clinical chemistry laboratory, Karolinska University Hospital, Solna. The basic 
principle of the test is to measure the ability of VWF to agglutinate platelets by binding 
to glycoprotein 1b (GP1b) receptor in the presence of ristocetin (an antibiotic that binds 
to both VWF and GP1b).  
 
3.5.2 ADAMTS13 
In study I we measured ADAMTS13 activity and antigen concentrations in plasma 
using the TECHNOZYM ADAMTS13 kit (Technoclone GmbH, Vienna, Austria). 
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Measurements were carried out at the Clinical Research Center at Danderyd Hospital. 
The method is based on the fluorogenic method described by Kokame et al. (155) and 
uses a small fluorogenic substrate for ADAMTS13 called FRETS-VWF73, a VWF-
fragment consisting of 73 amino acids. Plasma is incubated in micro wells coated with 
a monoclonal antibody specific for the extra cellular domain of ADAMTS13 which is 
thus attached to the wall of the well. After a washing procedure the substrate is added. 
This consists of both a fluorescent part and a part that extinguishes fluorescence. If the 
substrate is degraded by ADAMTS13 fluorescence is emitted and detected. The rate of 
fluorescence development is used to kinetically measure the ADAMTS13 activity, 
incubated at 30 °C and assayed at 360/460 nm. The antigen concentration is measured 
in the same samples by incubation with peroxidase labelled monoclonal antibodies 
towards ADAMTS13.  
Results are reported as a percentage of those from a pool of plasma from >100 healthy 
individuals. According to the manufacturer the reference interval for ADAMTS13 
antigen concentration is 75-110% and for ADAMTS13 activity concentration 50-110% 
of the pool. 
The CV for duplicates should not exceed 15% according to the manufacturer. The 
assay was run using a Tecan Infinite M220 multireader (Männedorf, Switzerland).  
The uncertainty was estimated from duplicate measurements of 48 samples in a study 
performed at our lab, and found to be 10.8% (SD), CV 9.6%, for ADAMTS13 activity 
and 6.4% (SD), CV 7.1%, for ADAMTS13 antigen 187.  
 
3.6 OTHER LABORATORY METHODS 
Commercially available kits and calibrators were used to measure all the quantities 
below, and the measurement procedures were carried out according to the 
manufacturer´s instructions and performed at the Clinical chemistry laboratory of 
Karolinska University Hospital, Solna: 
 
3.6.1 FVIII 
FVIII was measured using the COAMATIC FVIII reagent from Haemochrom 
Diagnostica (Essen, Germany). 
 
3.6.2 Fibrinogen 
Fibrinogen was analysed by Fibri-Prest Automate from Diagnostica Stago (Asnieres, 
France). 
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3.6.3 Routine analyses 
Concentrations of serum creatinine, sodium, potassium, plasma lipids, plasma glucose, 
CRP and blood cell counts were all measured by routine laboratory techniques. 
 
3.7 REGISTERS 
For study III we performed a cross-sectional study using linkage of Swedish population 
and health registers. We used the same registers for the cohort in study IV. 
MBR includes more than 99% of all births in Sweden since 1973 and consists of 
prospectively collected and validated information from the pregnancy, delivery and 
neonatal periods 188. 
The Swedish IVF Register is now a part of the Swedish Medical Birth Register (MBR) 
at the National Board of Health and Welfare and includes information on IVF 
pregnancies since 1982. 
The Swedish National Patient Register encompasses both inpatients and outpatients 189. 
Inpatient data in Sweden became available nationwide in 1987. Outpatient diagnoses 
from hospitals started to be collected in 1997. The register comprises date of admission 
and discharge, as well as main diagnosis with up to seven contributing diagnoses. Data 
in the Patient Register can be linked to other registers through the unique personal 
identity number assigned to all Swedish residents 190. 
Women´s education was found in the Register of Education, Statistics Sweden 191, by 
linkage through the personal identity number. 
For study III + IV the diagnoses were found by linkage to the Swedish Patient Register 
of the National Board of Health and Welfare 189. Diagnoses were recorded according to 
the International Classification of Diagnoses (ICD), ninth version in the time period 
1990 to 1996 and the tenth version from 1997 and onwards.  
For study III we used the following diagnoses for VTE: 415B, 451B, 452, 453C-D, 
453W, 453X, 671D-F and 673C in ICD-9 and I26.0, I26.9, I80.1- 3, I80.8-9, I82.2-3, 
I82.8-9, O22.3, O22.5, O87.1, O87.3, O87.9 and O88.2 in ICD-10.  
For study IV we used the diagnoses of hypertension, stroke, coronary heart disease and 
diabetes by the same linkage: 250, 401-405, 410, 411B, 412, 431, 433-434, 438, 642A-
D, 642X and 648A in ICD-9 and E10-11, E14, I10-13, I15, I20.0, I21-23, I25.2, I61, 
I63, I69.3-4, O10.0-4, O11.9, O13.9, O16.9 and O24 in ICD-10.  
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4 STATISTICAL ANALYSES 
An overview of the statistical analyses used in this PhD thesis is described below.  
For further details see Paper I-IV, respectively: 
• Students t-test – between groups with normally distributed variables, non-
normal distributed data were log-transformed and checked to be normally 
distributed before analysis.  
• Pearson’s correlation coefficient – to estimate if associations were present 
between normally distributed continuous variables, expressed as r values 
(Paper I-II). 
• Multiple regression – was used to assess the relationship between a dependent 
variable and one or more explanatory (independent) variables. 
• Cox proportional hazard regression - conditioned on matching sets was used 
to calculate Hazard ratios (HR) and 95% confidence intervals (95% CI) for 
VTE respectively PE in study III and for diagnosis events (end-points) of 
hypertension, diabetes, stroke and coronary heart disease in study IV. In study 
IV, the person-time for each woman was calculated from end of pregnancy to 
month of diagnosis of the end-point, month of death from other causes, 
emigration or to end of follow-up.  
 
For in-house statistical calculations Statistica software, version 8, by Statsoft Inc., 
Tulsa, Oklahoma, USA, was used. Data are presented as mean ± SD. Values of p<0.05 
were considered statistically significant.  
The conditional logistic regressions were performed in the Proportional Hazards 
Regression (PHREG) procedure of SAS, version 9.2, by SAS Institute Inc., Cary, NC, 
USA. 
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5 RESULTS  
5.1 PAPER I + II 
All patients were Caucasians in the ages 25-38 years and with normal resting blood 
pressures (<140/90 mm/Hg). None of them had a history of arterial or venous 
thrombosis. Basic characteristics of the patients are presented in table 2.  
Indications for IVF included female infertility in seven cases (anovulation in four 
women, ovarian dysfunction in two women and one had endometriosis), male infertility 
was present in twelve cases and unexplained infertility in twelve. 
Oestradiol increased 10-100-fold from <150 pg/mL at DR to a mean of 5889 pg/mL at 
HLS (range 1620–19500 pg/mL) as illustrated in figure 9.  
 
Figure 9. Oestradiol level changes from time of down-regulation (DR) to time of high 
level stimulation (HLS) in 31 women undergoing IVF treatment.  
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Twelve patients got pregnant and all except one were primigravidae. Three patients 
suffered a mild OHSS as defined by the Practice Committee of the American Society 
for Reproductive Medicine 101.  
 
5.1.1 Paper I 
VWF:Ag and VWF:RCoF activity increased by 41% respectively 49% (p<0.001) ) 
from the time of DR to HLS, and FVIII levels increased by 31% during the same time 
period (p<0.001). These changes were accompanied by a concomitant 6% decrease in 
ADAMTS13 antigen (p<0.05) and a 9% decrease in ADAMTS13 activity (p<0.01, 
table 3). The relative changes in ADAMTS13 antigen and activity from DR to HLS 
correlated significantly (r=0.7, p<0.001). 
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Table 2. Baseline characteristics of the 31 women enrolled in the study.  
  Patients Normal range 
Age, years  33.0  (±3.3)
Body mass index, kg/m² 24.1  (±3.6) <25 
Waist-hip ratio 0.8  (±0.1) <0.8 
Causes and type of infertility 
   Female, n (%) 7 (22.6%)
   Male, n (%) 12 (38.7%)
   Unknown, n (%) 12 (38.7%)
Current smoking, n (%)  2 (11.1%)
Triglycerides, mmol/l  0.8  (±0.4) 0.45-2.6 
Total cholesterol, mmol/l  4.9  (±0.7) 3.3-6.9 
LDL cholesterol, mmol/l  2.9  (±0.7) 1.4-4.7 
Creatinine, mmol/l  68.9  (±7.3) <90 
Plasma glucose, mmol/l  4.7  (±0.5) 4.0-6.0 
Haemoglobin, g/L 129.0  (±8.6) 117-153 
Haematocrit, % 0.39  (±0.02) 0.35-0.46 
Platelet count, x109 /L 251.2  (±47.6) 165-387 
 
 
Data are presented as mean (±SD) or n (%). 
We observed an inverse significant correlation between the concentration of VWF:Ag 
and the concentration of ADAMTS13 antigen and ADAMTS13 activity at the time of 
HLS (r=0.6, p=0.015 respectively r=0.5, p=0.026).  
The three OHSS patients had a 64% increase in VWF:Ag and a 63% increase in 
VWF:RCoF activity level from the time of DR to the time of HLS. FVIII increased 
56% during the same time period. These changes were accompanied by a 9% decrease 
in ADAMTS13 antigen and a 14% decrease in ADAMTS13 activity.  
Nine patients had blood group A (33%), eight had blood group AB (30%), seven had 
blood group O (26%) and three had blood group B (11%). In four of the women the 
blood group was unknown. We had few women with blood group O and a high 
percentage of women with blood group AB, which is probably a chance phenomenon 
due to the limited number of patients. The women with blood group O seemed to have 
lower VWF levels as compared to group mean; however, conventional statistical tests 
were not performed due to the low number of cases. 
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Table 3. Changes in haemostatic variables during IVF. 
  
Down 
regulation 
High level 
stimulation p-value 
Reference 
interval 
VWF:Ag, kIU/L 0.75 (±0.22) 1.06 (±0.40) <0.001 0.6 - 1.6 
VWF:RCoF activity, kIU/L 0.83 (±0.26) 1.24 (±0.48) <0.001 0.5 - 1.5 
ADAMTS13 antigen, % 72.2 (±13.5) 67.9 (±9.9) <0.05 75 - 110 
ADAMTS13 activity, % 88.6 (±18.3) 80.8 (±15.7) <0.01 50 - 110 
Factor VIII, kIU/L 0.96 (±0.34) 1.26 (±0.41) <0.001 0.5 – 1.8 
Fibrinogen, g/L 2.8 (±0.7) 3.3 (±0.7) <0.001 2 – 4 
Fibrin gel permeability, Ks 9.5 (±3.5) 8.6 (±3.0) 0.13 9.3 – 11.1 
OHP, Abs sum 7.7 (±2.9) 10.2 (±3.4) <0.001 4.2 – 14.5 
OCP, Abs sum 15.3 (±5.4) 19.5 (±5.5) <0.001 6.8 – 20.0 
OFP, Abs sum 48.2 (±11.7) 47.5 (±11.8) 0.75 16.5 – 52.0 
Clot lysis time, min 16.4 (±3.1) 17.1 (±3.7) 0.24 - 
ETP, nM IIa*min 1542 (±287) 1739 (±288) <0.001 1430 – 2273 
Lag time, min 2.7 (±0.6) 2.5 (±0.5) 0.001 2.1 – 2.9 
Peak, nM IIa 290 (±42) 343 (±38) <0.001 270 – 395 
ttPeak, min 5.3 (±0.7) 4.8 (±0.6) <0.001 4.4 – 5.7 
nAPCsr 1.4 (±0.7) 2.1 (±0.6) <0.001 2.3 - 2.6 
 
 
5.1.2 Paper II  
As shown in figure 10, the thrombin generation variables ETP (p<0.001) and peak 
height (p<0.001) were significantly raised at HLS as compared to DR. Concurrently 
there were decreases in lag time (p=0.001) and time to peak (p<0.001). We observed a 
32% increase in OHP (p<0.001) and a 27% increase in OCP (p<0.001) whereas OFP 
remained almost unchanged. Regarding fibrin gel permeability only a small (-9%) 
statistically non-significant reduction in permeability (Ks) was observed (p=0.13). 
Fibrinogen and FVIII concentrations in plasma increased by 19% (p<0.001) 
respectively 30% (p<0.001) from time of DR to HLS. All changes in haemostatic 
variables during IVF are shown in table 3. 
Although significant changes toward a procoagulable state were observed in the 
variables of thrombin generation as well as of fibrin formation, all remained within the 
reference interval. The significant results persisted after exclusion of three patients who 
later developed OHSS. 
Multiple regression analyses showed that the change in FVIII from DR to HLS 
explained a part of the change in OHP (r=0.49, p=0.024), whereas ETP could explain a 
part of the variation in OCP (r=0.70, p<0.001). Further multiple regression analyses 
showed that fibrinogen and FVIII explained a part of the variation in peak height 
(r=0.47, p=0.031). At the time of HLS, plasma fibrinogen significantly explained a part 
of the variation in OHP (r=0.65, p=0.002).  
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conception (unexposed) had an almost identical mean age (33.3 ± 4.0 and 33.4 ± 3.9, 
respectively).  
The proportion of multiple births in the women who had undergone IVF was 16.9%. 
Women in the IVF group had a higher educational level (47.1% had >12 years of 
education), were in a less frequency smokers (6.7%) and a higher proportion of them 
were born in Sweden (86%) as compared to the control group. See table 4 for further 
details about the two groups of women. 
 
Table 4. Characteristics of women from IVF register and Medical Birth Register 
(MBR) during the time period 1990–2008. 
 
  Women from IVF register Women from MBR
Total number n=23,498 n=116,960
Mean age (±SD) 33.3 (±4.0) 33.4 (±3.9)
Median age (quartiles) 33 (31;36) 33 (31;36)
Single/multiple birth 
Single birth 83.1% 97.4%
Multiple births 16.9% 2.6%
Mothers born in Sweden 86.2% 81.4%
Prepregnancy BMI 
Missing 16.9% 17.3%
<25 53.2% 53.4%
 25-29 21.9% 21.1%
 ≥30 8.1% 8.2%
Smoking habits 
Missing 7.6% 6.6%
No 85.7% 82.9%
<10 cigarettes/day 4.9% 6.7%
≥10 cigarettes/day 1.8% 3.8%
Education (years) 
Missing 0.2% 0.9%
≤9 7.6% 10.0%
10-12 45.1% 43.2%
>12  47.1% 45.9%
PCOS, n (%) 788 (3.4%) 563 (0.5%)
Preeclampsia, n (%) 1646 (7.0%) 6117 (5.2%)
Hypothyroidism, n (%) 447 (1.9%) 1790 (1.5%)
 
 
5.2.1 Paper III 
The proportion of VTE in the exposed group was 4.2/1000 (n=99) as compared to 
2.5/1000 (n=291) in the unexposed women (table 5).  
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Table 5. Venous thromboembolism and pulmonary embolism events in the two 
groups of pregnant women expressed as numbers and percentages. 
 
Events in relation to pregnancy 
 IVF pregnancies  
n (%) 
Normal pregnancies  
n (%) 
Proportional hazard 
regression (95% CI) 
Venous thromboembolism:    
 Prepregnancy 71 (0.30) 415 (0.35) 0.85 (0.66 - 1.10) 
 Pregnancy and delivery 99 (0.42) 291 (0.25) 1.77 (1.41 - 2.23) 
 Days 43-365 postpartum 24 (0.10) 95 (0.08) 1.29 (0.82 - 2.02) 
Pulmonary embolism:    
 Prepregnancy 21 (0.09) 103 (0.09) 1.04 (0.65 - 1.66) 
 Pregnancy and delivery 19 (0.08) 70 (0.06) 1.42 (0.86 - 2.36) 
 Days 43-365 days postpartum 3 (0.01) 26 (0.02) 0.60 (0.18 - 1.98) 
 
 
As shown in table 5, the incidence of VTE after IVF was increased during all 
pregnancy (P<0.001; HR 1.77, 95% CI 1.41-2.23) and differed between the trimesters 
(P=0.002, figure 12 and table 6). The risk was in particular increased during the first 
trimester (1.5/1000 v 0.3/1000, HR 4.05, 95% CI 2.54-6.46). The risk did not differ 
between the two groups of women before pregnancy (HR 0.85, 95% CI 0.66-1.10) and 
during the year after delivery (HR 1.29, 95% CI 0.82-2.02). 
PE occurred in 19 women in the IVF group (8.1/10,000) as compared to 70 of the 
matched women (6.0/10,000). The incidence was increased after IVF (P<0.01; HR 
1.42, 95% CI 0.86-2.36) and differed between the trimesters (P=0.0092). The incidence 
was in particular increased during the first trimester (3.0/10 000 v 0.4/10 000, HR 6.97, 
95% CI 2.21-21.96), see figure 12 and table 7. 
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Figure 12. Proportional hazard regression of venous thromboembolism and pulmonary 
embolism in pregnant women after IVF (n=23 498) and in natural pregnancies  
(n=116 960). 
 
 
Figure 13. Proportional hazard regression of venous thromboembolism in three strata 
for body mass index (<25, 25-29.9, and ≥30) in pregnant women after IVF (n=23 498) 
and in women with natural pregnancies (n=116 960). 
 
P<0.01 
P<0.001 
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Table 7. Time to first event of pulmonary embolism in the two groups of women. 
Values are numbers (percentages) unless stated otherwise. 
 
 
Variables  
IVF  
Pregnancies 
(n=23 498) 
Normal 
pregnancies
(n=116 960) 
Proportional hazard 
regression (95% CI) 
First trimester (weeks 1-12) 7 (0.03) 5 (0.004) 6.97 (2.21 - 21.96) 
Second trimester (weeks 13-25) 5 (0.02) 13 (0.01) 0.42 (0.05 - 3.20) 
Third trimester (week 26 to <3 days 
before birth) 
6 (0.03) 18 (0.02) 0.40 (0.10 - 1.68) 
≤3 days before to 42 days after birth 11 (0.05) 49 (0.04) 1.79 (0.86 - 3.74) 
P value for test of difference* — — 0.0034 
Test of equal effect in all time 
periods† 
— — 0.0092 
*Wald χ2 for difference between IVF and controls. 
†Wald χ2 test. 
 
No significant interaction was observed between BMI and IVF concerning incidence of 
VTE (P=0.21). The incidence in women who did not undergo IVF, however, increased 
as expected by BMI level (P<0.001, figure 13), but no such effect was observed in 
women after IVF (P=0.46, figure 13). 
Further multivariable analyses taking calendar period, parity, single or multiple births, 
smoking, education, maternal age, country of birth, and marital status into account were 
carried out and we stratified on BMI in two categories: <25 and 25-29.9 (table 8). 
These adjustments did not alter the significance of the main finding.  
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Table 8. Multivariable analysis stratified on body mass index (BMI) in pregnant 
women with BMI <30. 
 
Variables 
Hazard ratio (95% CI) 
BMI <25 BMI 25-29.9 
Adjusted by 
conditioning on BMI  
Normal pregnancy 1=reference 1=reference 1=reference 
IVF pregnancy:    
First trimester  5.21 (2.68 - 10.14) 2.40 (0.85 - 6.80) 4.13 (2.37 - 7.17) 
Second trimester  0.91 (0.34 - 2.46) 1.78 (0.53 - 5.93) 1.18 (0.55 - 2.51) 
Third trimester  1.17 (0.53 - 2.58) 1.38 (0.57 - 3.33) 1.25 (0.69 - 2.25) 
Three days before to 42 days 
after birth 
1.10 (0.56 - 2.17) 1.27 (0.59 - 2.75) 1.16 (0.69 - 1.93) 
P value for test of difference* <0.001 0.77 <0.001 
Test of equal effect in all time periods† 0.001 0.42 0.0017 
No of older siblings:    
 None 1=reference 1=reference — 
 ≥1 0.92 (0.65 - 1.30) 1.36 (0.58 - 3.19) 0.83 (0.63 - 1.1) 
Single birth 1=reference 1=reference  
Multiple births 2.52 (1.49 - 4.25) 1.33 (0.57 - 3.13) 2.06 (1.32 - 3.21) 
Smoking at start of pregnancy:    
 No 1=reference 1=reference — 
 Yes 0.91 (0.49 - 1.68) 0.89 (0.45 - 1.77) 0.89 (0.56 - 1.41) 
Education (years):    
 ≤9 1=reference 1=reference — 
 10-12 1.16 (0.57 - 2.39) 0.55 (0.27 - 1.12) 0.88 (0.53 - 1.44) 
 >12 1.26 (0.61 - 2.59) 0.80 (0.40 - 1.62) 1.06 (0.64 - 1.75) 
Maternal age at delivery (years):    
 <35 1=reference 1=reference — 
 ≥35    
  First trimester (weeks 1-12) 0.84 (0.43 - 1.63) 2.34 (0.85 - 6.45) 1.14 (0.67 - 1.96) 
  Second trimester (weeks 13-25) 0.60(0.25 - 1.43) 2.25 (0.73 - 6.88) 0.92 (0.48 - 1.75) 
  Third trimester (week 26 to <3   
before birth) 
0.60(0.30 - 1.23) 1.20 (0.58 - 2.49) 0.84 (0.51 - 1.38) 
  ≤3 before to 42 days after birth 1.53 (0.91 - 2.57) 2.64 (1.41 - 4.96) 1.88 (1.26 - 2.78) 
Country of birth:    
 Sweden 1=reference — — 
 Other country 1.14 (0.72 - 1.83) 3.06 (1.45 - 6.44) 1.62 (1.09 - 2.41) 
Calendar period:    
 1990-2001 1=reference 1=reference 1=reference 
 2002-2008 1.55 (1.12 - 2.14) 2.64 (1.64 - 4.25) 1.86 (1.43 - 2.43) 
Marital status:    
 Cohabiting with father of child 1=reference 1=reference 1=reference 
 Other 0.81 (0.29 - 2.21) 1.34 (0.53 - 3.36) 1.03 (0.52 - 2.03) 
*Wald χ2 for difference between IVF and no IVF. 
†Wald χ2. 
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5.2.2 Paper IV 
We used the same cohort of women as in study III, and the baseline characteristics of 
the study sample from 1990 to 2008 are thus given in table 4.  
Less than 3% women emigrated and 0.5% died during follow-up. The mean follow-up 
time in the IVF and control group was 8.6 ± 4.6 respectively 8.6 ± 4.9 years, 
contributing to 201 498 respectively 1 000 368 person-years at risk (table 9). 
 
Table 9. Follow-up time and drop-out frequency of the women in the study. 
 
  IVF women  Control women  
n % n % 
Total number  23 498 116 960   
Possible to follow until  
end of follow-up 22 911 97.5 113 158 96.8 
Emigrated 471 2.0 3 215 2.8 
Deceased 116 0.5 587 0.5 
    
Total years of follow-up 201 948 1 000 368   
Mean follow-up in years (±SD) 8.6 (±4.6) 8.6 (±4.9)   
 
 
During this period, 823 women developed a first event (diabetes, n=201; hypertension, 
n=520; coronary heart disease, n=23; stroke, n=79). As shown in table 10, the 
proportion of women with hypertension and stroke was slightly greater in the IVF 
group as compared to the MBR controls. 
Multivariable analysis adjusted for BMI, smoking, country of birth and educational 
level showed a higher incidence of hypertension among IVF women (HR 1.27, 95% CI 
1.13-1.41) as compared to mothers after natural conception (table 11). There was a 
trend towards a higher risk of stroke (HR 1.27, 95% CI 0.96-1.68) but the incidence of 
coronary heart disease or diabetes did not differ after IVF pregnancies as compared to 
the controls (HR 0.72, 95% CI 0.44-1.17 and HR 0.96, 95% CI 0.81-1.14).  
When looking at the whole group of women, those who were smoking more than 10 
cigarettes on a daily basis had a much higher risk of coronary heart disease as 
compared to non-smokers (HR 5.46, 95% CI 3.55-8.40). Even women smoking less 
than 10 cigarettes daily had a higher risk compared to the non-smokers (HR 4.16, 95% 
CI 2.81-6.18. 
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Table 10. Total number and incidence per 10.000 person-years of diabetes, 
hypertension, coronary heart disease and stroke in women from the IVF and Medical 
Birth Register 1990-2008. 
 
      IVF women    Control women  
    n Incidence 95% CI n Incidence  95% CI 
  23498 
per 10.000  
person-years   116960 
per 10.000 
person-years   
Diabetes   201 9.95 8.65-11.4 1 111 11.1 10.47-11.77 
Hypertension 520 2.58 2.36-2.80 2 129 2.13 2.04-2.22 
Coronary heart disease 23 1.14 0.74-1.68 185 1.85 1.60-2.13 
Stroke  79 3.91 3.12-4.85 319 3.19 2.85-3.55 
Total number 823 4.08 3.80-4.36 3744 3.74 3.62-3.86 
 
Furthermore, as expected, an increase in BMI resulted in a higher incidence of CVD. A 
BMI higher than 30 increased the incidence of diabetes (HR 5.25, 95% CI 3.09-7.07), 
coronary heart disease (HR 5.23, 95% CI 2.34-11.72) and hypertension (HR 3.84, 95% 
CI 3.07-4.82), whereas stroke incidence was not affected (HR 1.15, 95% CI 0.70-1.90). 
All univariable and multivariable analyses are shown in table 11.  
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Table 11. CVD hazard ratios (HR) and 95% confidence intervals (95% CI) among 
Swedish women giving their first delivery from 1990 to 2008 with additional 
adjustments for BMI, smoking, country of birth and educational level. 
 
      Diabetes Hypertension 
Coronary heart 
disease Stroke  
      HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Univariable analysis   
MBR group 1=reference 
IVF group 0.90 (0.77-1.05) 1.24 (1.13-1.37) 0.65 (0.42-1.00) 1.24 (0.97-1.58) 
Univariable analysis with 
exclusion^ 
MBR group 1=reference 
IVF group   0.90 (0.76-1.07) 1.26 (1.13-1.41) 0.64 (0.39-1.05) 1.22 (0.92-1.61) 
Multivariable analysis* 
MBR group 1=reference 
IVF group 0.96 (0.81-1.14) 1.27 (1.13-1.41) 0.72 (0.44-1.17) 1.27 (0.96-1.68) 
Country of birth 
Sweden 1=reference 
Other 2.14 (1.86-2.46) 0.99 (0.87-1.11) 1.21 (0.81-1.80) 1.40 (1.05-1.87) 
BMI before pregnancy 
<20 1=reference 
20-24.9 1.00 (0.75-1.35) 1.39 (1.13-1.72) 1.46 (0.67-3.20) 0.89 (0.59-1.32) 
25-29.9 2.02 (1.50-2.72) 2.23 (1.8-2.77) 2.37 (1.07-5.25) 1.07 (0.70-1.64) 
>30 5.25 (3.09-7.07) 3.84 (3.07-4.82) 5.23 (2.34-11.72) 1.15 (0.70-1.90) 
Smoking 
No 1=reference 
<10 cigarettes/day 0.88 (0.69-1.11) 1.06 (0.90-1.25) 4.16 (2.81-6.18) 1.12 (0.74-1.70) 
≥10 cigarettes/day 1.31 (1.02-1.68) 1.25 (1.03-1.53) 5.46 (3.55-8.40) 1.83 (1.18-2.83) 
Education 
Primary school 1.37 (1.15-1.62) 1.10 (0.95-1.28) 1.48 (1.00-2.21) 1.43 (0.8-2.58) 
High school 1=reference 
More than 12 years   0.79 (0.68-0.91) 1.10 (1.00-1.21) 0.95 (0.64-1.42) 1.08 (0.85-1.37) 
 
^ Univariable analysis with exclusion of women lacking information on smoking and BMI  
* Multivariable analysis with additional adjustments for BMI, smoking, country of birth and educational 
level. 
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6 GENERAL DISCUSSION 
Both venous and arterial thrombotic diseases pose major health problems. The four 
studies in this thesis comprise different perspectives on thromboembolism with aspects 
from the fields of internal medicine, cardiovascular epidemiology, gynaecology and 
laboratory medicine.  
 
6.1 VENOUS THROMBOEMBOLISM DURING IVF 
We identified an increased incidence of VTE during all trimesters of pregnancies after 
IVF as compared to during the trimesters of pregnancies after natural conception. The 
risk was in particular pronounced during the first trimester.  
The distribution of PE and VTE during the trimesters after IVF (figure 12 and table 6) 
contrasted to that after natural conception. The risk of VTE and PE after natural 
conception is at its highest during the postpartum period 192-194.  
Numerous case reports of VTE during IVF pregnancies have been published and 
reviewed repeatedly 25, 106, 195. One of the main reasons for the attention of these case 
reports is the localization of thromboses at unusual sites, such as in vessels of the upper 
extremities and neck. A general statement in these reviews has been that the risk of 
VTE is comparable to that of normal pregnancy 106. However, this contention is clearly 
rejected by the present thesis as we found a significantly increased incidence of VTE 
during all trimesters and in particular during the first trimester. The close time relation 
to the IVF procedure suggests that changes induced by the procedure by itself could be 
of pathophysiological importance. A plausible initiator of adverse mechanisms could be 
the noticeable increase in endogenous oestrogen levels during the stimulation phase of 
treatment before the actual IVF procedure 25.  
In our study we did a separate analysis of PE cases. The risk of PE in women after IVF 
was increased almost sevenfold during the first trimester, although the absolute risk 
was low (2-3 additional cases of PE per 10 000 pregnancies). PE is a leading cause of 
maternal death 95, 96, and our finding is therefore important to clinicians consulted by 
women who are pregnant after IVF. 
Use of exogenous oestrogens has consistently been associated with an increased 
incidence of VTE, irrespective of the indication of its use. The first adverse report on 
the use of this hormone was in women using oestrogen containing contraceptive pills 
196 and recently also in women using oestrogen after menopause 197, 198. The risk of 
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VTE in the largest randomized study was doubled as compared to placebo (HR 2.06; 
95% CI 1.57-2.70) 197. Notably, increased cardiovascular events have been shown also 
in males receiving oestrogen due to testosterone dependent prostatic carcinoma 199.  
The validity of the Patient Register is generally considered to be high, and has 
previously been used to estimate the incidence of VTE during pregnancy during the 
time period 1990-93 16, 189, 190. We found a similar incidence as Lindqvist et al. 16 in 
unexposed women during that time period in the present study. However, as earlier 
mentioned, VTE events in both exposed and unexposed women seem to increase 
during the first decade of the new millennium. A contributory reason for this could be 
the inclusion of outpatient diagnoses. There could also be an increased awareness of 
VTE during pregnancy. A high baseline index for suspicion of VTE during pregnancy 
is critical for diagnosis because many of the clinical signs and symptoms of VTE are 
common also in normal pregnancies 194, 200. Improvement in diagnostic procedures, 
including a more extensive use of ultrasound examinations, has probably contributed to 
the increased incidence of VTE 194.  
A limitation of MBR is that it only includes women with deliveries. Thus, an obvious 
bias is that more complicated pregnancies resulting in fatal outcomes to the mothers 
were not included. This might, in fact, result in an underestimation of the true risk of 
VTE and in particular PE during IVF pregnancy.  
A further potential weakness could be an influence of parity on the propensity to suffer 
thrombosis. However, primigravidae also had an increased risk of VTE as compared to 
normal pregnancy. Another bias could be the presence of thrombophilia including the 
antiphospholipid syndrome as this might influence fertility 201, 202.  
The risk of VTE increased as expected by level of BMI in the control group but this 
relation was not found in IVF women (figure 13). This latter finding was unexpected 
since increased BMI is known to increase the risk of VTE. We speculate whether direct 
action and production of oestrogen in fat tissue in obese women might cause a higher 
basic oestrogen level and therefore a less pronounced “oestrogenic change” during IVF 
treatment 203. Furthermore, VTE might be overrepresented in women with OHSS due to 
capillary leakage and haemoconcentration 102 and OHSS is more prevalent in lean 
women 101, 105.  
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6.2 HAEMOSTATIC DISTURBANCES DURING PREGNANCY AND IVF 
Studies of individual coagulation factors disclose a clear increase in VWF, FVIII, 
fibrinogen, as well as increased APC resistance, together with reduced AT, proteins C 
and S activity when ovarian stimulation occurs 141, 146, 204-206. Our results, showing 
increased levels of FVIII, VWF, fibrinogen and nAPCsr during IVF are therefore not 
surprising. Totally, the individual factors seem to change towards a procoagulable state 
during IVF. 
 
6.3 GLOBAL HAEMOSTASIS ASSAYS 
Study II is the first study in which the global haemostasis assays CAT, OHP and the 
fibrin gel permeability assay have been investigated and compared during IVF 
treatment. We were able to demonstrate a highly significant increase in ETP and OHP 
concomitant with an approximately 38 times increase in circulating oestradiol 
concentration from time of DR to HLS. 
We investigated two parts of the coagulation process, i.e. thrombin generation (CAT 
assay) and fibrin formation (OHP assay). The OHP and CAT assays differ both in the 
end product of measurement but also in the use of different triggers of coagulation. The 
OHP assay uses thrombin whereas the CAT assay uses TF as trigger. As both methods 
have a global approach, their responses are dependent on several factors present in the 
plasma sample, making it impossible to specifically delineate the mechanism. The OHP 
assay showed that women undergoing IVF treatment had increased fibrin formation. 
The CAT data indicate that this may, at least in part, be due to increased thrombin 
generation. 
 
6.3.1 Calibrated Automated Thrombogram 
Thrombin generation is augmented during IVF as demonstrated by the increase in both 
ETP and peak height, together with a decreased time to thrombin generation (lag phase) 
and time to peak of thrombin generation. Thrombin generation results as detected by 
the CAT method may provide information different from measurements of single 
markers of ongoing thrombin generation, i.e. F1+2 or TAT, which assess the in vivo 
thrombin formation. Thus, the CAT analysis may better reflect the physiologic 
prothrombotic tendency by stimulation with TF, which is considered to be the main 
coagulation trigger. Upon adding APC to the reagents in the CAT assay, the normalized 
APC sensitivity ratio (nAPCsr) significantly increased from DR to HLS which 
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indicates that IVF treatment causes an acquired form of APC resistance. This result is 
in line with Curvers et al. who were able to show that nAPCsr increased slightly at DR 
and significantly during HLS and remained even high during luteal support 52.  
Some clinical studies suggest that peak thrombin concentration is the most informative 
variable indicating procoagulability in an individual setting 207. However, there was a 
large interindividual variability in both ETP and peak thrombin concentration in our 
IVF patients. This inter individual variability could in part be due to a different 
pathophysiology of infertility among these women, but other clinical factors may also 
have a considerable influence, i.e. twin pregnancy. The analysis of these variables 
during the high oestrogen level phase caused by normal pregnancy, preeclampsia and 
oral contraceptive use showed similar patterns 78, 79, 208. 
There are two different CAT assay approaches, i.e. the chromogenic method with 
defibrinated plasma and the fluorogenic method. We used the latter more sensitive 
method, which assesses thrombin generation in the presence of fibrinogen. 
Methodological differences are also the use of platelet rich versus platelet poor plasma. 
The fluorogenic method uses platelet poor plasma and the thrombin generation is 
therefore not affected by platelet function. Instead, a standard amount of procoagulant 
phospholipids are added to the platelet poor plasma sample. 
 
6.3.2 Overall Haemostasis Potential 
During controlled ovarian hyperstimulation in study II, OHP increased significantly 
from the time of DR to HLS. Change in OHP was partly determined by change in 
FVIII level, as demonstrated by a statistically significant correlation between OHP on 
one side and the concentration of this coagulation protein on the other side. An 
additional measure in this global haemostasis assay - the Overall Coagulation Potential 
(OCP) - was significantly increased and correlated to ETP levels at the time of HLS 
reflecting enhanced fibrin generation in the IVF patients.  
Previous studies by our group have confirmed the sensitivity of the OHP method to 
detect the presence of a procoagulable state when circulating oestrogen levels are 
elevated. Along with increased gestational age in pregnant women OHP and OCP 
increased and OFP decreased 77. Furthermore, hormone replacement treatment with 
high-dose oral oestrogens in postmenopausal women caused an activation of 
coagulation and a decrease in fibrinolysis as measured by the OHP assay 167.  
To our knowledge, the study by Harnett et al. 72 was the only study utilizing a global 
haemostasis assay by thromboelastography in IVF patients. Aligned with their findings 
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of a significant decrease in clot formation time and an increase in clotting index at the 
time of oocyte retrieval, our results demonstrate that isolated high oestrogen 
concentrations, as produced by an IVF protocol, associate with a procoagulable state. 
This condition could potentially lead to thrombotic complications that can markedly 
affect the quality of life, and in fact, also in some cases be fatal to these women.  
The studies of fibrinolytic variables during IVF are somewhat contradictive 
demonstrating both a down regulation and activation of fibrinolysis 27, 56, 68. The overall 
fibrinolysis potential (OFP) and clot lysis time (CLT) investigated in the present study 
were not significantly altered during IVF procedure, and remained within the reference 
range both at DR and HLS. It thus seems that the fibrinolytic system is not significantly 
affected by the IVF treatment. 
 
6.3.3 Fibrin network  
The non-significant decrease in fibrin gel permeability was surprising as increased 
thrombin generation may be expected to induce a tighter and more stable fibrin gel. 
However, we used a relatively high concentration of thrombin to initiate clot formation 
in our assay so endogenous thrombin generation should not influence the characteristics 
of the fibrin network formed. The observed increase in fibrinogen concentration could 
only partly influence the results of fibrin gel permeability. Fibrin polymerization rates 
as well as altered levels of fibrinogen-binding proteins (such as FXIII) are additional 
mechanisms that may affect fibrin gel porosity and deserve further investigations.  
 
6.4 VON WILLEBRAND FACTOR AND ADAMTS13 
In our study we analyzed both VWF and ADAMTS13 to study their inter relationships. 
We found a rapid increase in VWF:Ag and VWF:RCoF activity levels together with 
increased FVIII levels and decreased ADAMTS13 antigen and activity levels in 
parallel with the on average 38 times higher oestradiol plasma levels during the middle 
stage of IVF treatment.  
 
6.4.1 Von Willebrand factor 
VWF contributes to coagulation by stabilizing FVIII, which is an essential blood 
clotting factor. A high plasma level of FVIII is a risk factor for VTE 204, 205. In our 
study, the rise of FVIII concentration by 31% is similar to previously reported data 35 in 
patients undergoing IVF, suggesting a procoagulant state during the course of ovarian 
 50 
 
stimulation. Still, since the concentrations of VWF and FVIII are strongly related, it 
may be difficult to unravel separate effects of these proteins on a putative development 
of a procoagulable state during IVF. Clearly, other oestrogen-related mechanisms, such 
as direct effects on endothelial cells, may be active in the regulation of VWF levels 
observed during IVF 206. 
In fact, we know that the large multimers of VWF are necessary for an optimal 
haemostasis 209. In our study we analyzed only the total level and activity of VWF, as 
the method of analyzing VWF multimers was not well standardized at our laboratory at 
that point of time.  
VWF seems to add predictive power irrespective of risk score, both for bleeding and 
cardiovascular events 210, 211. Measurement of VWF levels are therefore of limited value 
in clinical practice since patients with a high level will have a high risk of both 
cardiovascular events and bleeding complications.  
 
6.4.2 ADAMTS13 
Study I is the first report of changes in circulating ADAMTS13 antigen and activity 
levels during IVF. As ADAMTS13 is the VWF-cleaving protease, we found an inverse 
correlation between VWF and ADAMTS13 at the time of high endogenous oestrogen 
concentration. With a correlation coefficient of 0.5 we could assume that around 25% 
of the variability in VWF levels in our study could be explained by changes in the 
levels of ADAMTS13.  
Our results support the idea that oestrogen is of importance in the regulation of 
ADAMTS13 levels. However, it remains unclear if the decrease of ADAMTS13 levels 
in IVF patients is due to inhibition of its enzymatic activity, to consumption of the 
protease, or to increased clearance from plasma. Furthermore the concentrations of 
VWF:Ag at the time of HLS were inversely correlated to ADAMTS13 antigen and 
activity suggesting that changes in ADAMTS13 could partly influence VWF levels.  
In our study we clearly showed that not only the antigen concentration of ADAMTS13 
but also the activity of this enzyme was reduced during the high oestrogen levels in this 
phase of the IVF procedure. Measuring both ADAMTS13 antigen and activity helped 
us to understand whether or not the protease was fully active, and provides a new tool 
for understanding the physiology and pathophysiology of ADAMTS13 212.  
ADAMTS13 is a molecule that influences haemostasis ”outside” the tissue factor 
induced pathway of coagulation. This is of interest in the development of future and 
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new drug targets. Such strategies could have a potential to attenuate thrombosis without 
increasing bleeding. 
 
6.5 LIFE STYLE ASPECTS 
Haemostatic factors may be influenced by lifestyle changes. An increase in physical 
activity has positive effects on thrombin generation as measured by F1+2 in plasma 213 
and obesity is associated with elevated thrombin generation 214. Three out of 31 women 
in the IVF group were obese (BMI>30), but obesity in general was not a large clinical 
problem in this patient group with a mean BMI of 24.1 kg/m². Smoking has negative 
effects on fibrin network tightness 215. Only two of our patients were smokers, and it is 
reasonable to assume that to stop smoking may beneficially influence the fibrin 
network tightness. 
 
6.6 CARDIOVASCULAR DISEASE IN WOMEN 
The main result of study IV is a higher incidence of hypertension in women who had a 
child born after IVF than in women who delivered after natural conception during the 
time period 1990-2008. These IVF mothers also had a trend towards a higher incidence 
of stroke, while the incidence of coronary heart disease and diabetes did not differ 
between the two groups of women.  
The main advantage of our study is the sample size and the prospective nature. To get a 
representative group of controls we included five control women for every IVF woman 
and were able to retrieve data about smoking, BMI, country of birth and education by 
matching of relevant registers. Furthermore, the result of our study is in accordance 
with the study of Parikh et al, which was conducted on Swedish women with self-
reported data of subfertility in the Swedish MBR 216.  
Women in the IVF group were less often smokers, had a higher educational level and a 
lower proportion of women in this group were born abroad. Even though these life 
circumstances might indicate a reduced risk of CVD, the IVF women had a higher 
incidence of hypertension than control women. The number of CVD events, coronary 
heart disease (n=23) and stroke (n=79), in the 23.498 women in the IVF group was 
small. However, when looking at the effects of the other risk factors in the whole group 
of women (table 11), we found as expected that obese women (BMI>30) had a higher 
incidence of diabetes, coronary heart disease and hypertension. 
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We suggest that the number of women and the mean age in the present study were too 
low and the mean follow-up period of 8.6 years too short to induce a high enough 
cardiovascular event rate to reach reasonable statistical power. Due to the steady 
increase in numbers of IVF treated women, most of our included women had their IVF 
treatment after 2000. This resulted in a mean age at inclusion of 33 years, and a mean 
age at end of follow-up of only 41 years.  
Despite the low mean age of the women, when stratifying the whole group into 
different subgroups of smoking, those who were smoking more than 10 cigarettes daily 
had an increased risk of coronary heart disease as compared to non-smokers. 
Smoking is associated with a risk of a two years earlier onset of menopause 217 and 
smoking is also one of the most important determinants of coronary heart disease in 
women 218, 219. 
As in previous reports, preeclampsia was overrepresented in the IVF group, and the 
condition is a well-known risk factor for the development of CVD later in life 220, 221. 
Actually, the risk has been found to be more than doubled as compared to those with 
uncomplicated pregnancy 222. Preeclampsia occurs in 3-5% of normal pregnancies, and 
in our IVF group there were 7% women with preeclampsia as compared to 5.2% of the 
women in the control group.  
Diagnoses of hyperlipidaemia and cholesterol levels are not included in study IV. 
Hyperlipidaemia diagnosis codes are not frequently used in registers in general and has 
thus a low validity. This is a limitation of our study since especially 
hypercholesterolaemia is an important CVD risk factor 223. Differences in cholesterol 
levels between the two groups could have affected the results of the study. As the 
women in the IVF group could have a lowered risk of CVD due to life circumstances 
this could well affect lipid levels. Two other possible confounders in this study could 
be physical activity and alcohol intake, as these have an impact on the risk of CVD.  
 
6.7 INFERTILITY 
In a recent report female infertility accounted for 64% of all infertile couples and 19% 
were due to male infertility. The remaining 17% had an unknown cause 224. 
Unfortunately, we have no information about the causes of infertility in our 23.498 IVF 
women in studies III + IV, but male infertility cases may have diluted our results 
causing an underestimation of the true difference. 
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PCOS, prevalent in 6-8% of women in the reproductive ages 225, accounts for up to 
15% of female infertility and is associated with subclinical atherosclerosis as measured 
by carotid intima-media thickness and endothelial dysfunction 226. The number of 
women with PCOS was higher in the IVF group than in the control group, but the 
proportion was low in both groups. We speculate that the condition is underreported in 
the registers. 
Excess adiposity as assessed by BMI is associated with subfertility 227 and incident 
CVD 228. However, adjustment for BMI neither nullified nor attenuated our CVD risk 
estimates, suggesting that factors other than BMI underlie the increased incidence of 
hypertension in the IVF group. 
Another possible mechanistic link between infertility and CVD is hypothyroidism, 
which is linked both to infertility 229 and incident CVD 230. However, in our material, 
the prevalence of hypothyroidism was low in both the study and control group. 
Therefore, we assume that this condition did not affect the result. 
 
6.8 GENERAL REMARKS 
In summary, in study I+II we have shown haemostatic changes during IVF pre-
treatment which may contribute to the higher incidence of VTE during the first 
trimester of IVF pregnancies as shown in study III.  
This is the first study of CAT and OHP as well as of fibrin gel permeability in IVF 
patients establishing reference intervals of these variables which could differentiate 
them from normal pregnant women or female patients treated with exogenous 
oestrogens. Global assays of haemostasis can provide a possibility to assess the 
haemostatic balance during IVF when it is used as a complement to conventional risk 
factor evaluation for VTE. 
We conclude that supraphysiologic oestrogen concentrations gained during IVF exert 
pronounced effects on blood clotting which potentially could lead to thrombotic 
complications.  
After gaining new information from our studies in this thesis we suggest revising the 
National Guidelines regarding thromboprophylaxis during IVF and we recommend 
considering thromboprophylactic treatment more frequently to patients at risk during 
the first 12 weeks after embryo transfer. 
To our knowledge, study IV in this thesis is the first prospective cohort study 
investigating whether CVD and related risk factors have a higher incidence in women 
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after IVF pregnancy as compared to women who delivered after natural conception. 
The IVF women in our study had a higher incidence of hypertension than control 
women in the years after delivery. Hypertension is a main risk factor for CVD but there 
is a long time delay between the initiation of vascular disease processes and manifest 
CVD such as coronary heart disease and stroke 231. Therefore, we speculate that female 
infertility could be associated with a higher risk of CVD later in life. We recommend 
that clinicians should pay a close attention to and measure blood pressure in women 
who have passed an IVF treatment as they seem to have a higher propensity to develop 
hypertension. These women should be offered antihypertensive treatment if blood 
pressure increases above reference levels in order to prevent vascular damage. 
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7 CONCLUSIONS 
• IVF treatment is associated with an increased incidence of VTE and PE during 
pregnancy.  
• IVF treatment leads to an alteration of haemostasis towards a procoagulable 
state including: 
o Increased thrombin generation (CAT assay) 
o Increased fibrin formation (OHP assay) 
o Increased plasma levels and function of VWF  
o Decreased plasma levels and function of ADAMTS13  
• Women undergoing IVF pregnancies have a higher incidence of hypertension 
and even a trend towards a higher incidence of stroke in the years after 
delivery compared to women who deliver after natural conception. 
• Women undergoing IVF pregnancies did not seem to differ in the incidence of 
coronary heart disease and diabetes, as compared to women who delivered 
after natural conception. However, the time of follow-up in the cohort was too 
short to reject a long-term difference between the two groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
 
8 FUTURE PERSPECTIVES 
The higher incidence of VTE and PE during pregnancy after IVF treatment should 
result in more frequent use of thromboprophylaxis in these women.  
Further prospective clinical studies are needed to establish the role of ETP and OHP as 
risk predictors of future thrombotic events during IVF treatment and as tools to monitor 
the IVF treatment. 
Further research is also needed to increase the understanding of a possible 
pathophysiological role of ADAMTS13 in thrombosis. ADAMTS13 is an interesting 
drug target in the future with a potential to reduce thrombosis development without 
increasing bleeding.  
Furthermore, additional mechanistic studies are needed to elucidate the long-term 
effects of IVF on global haemostasis during pregnancy, especially during the first 
trimester. 
With the currently increasing age when couples start family planning in the Western 
world there will probably be even more infertile couples in the future. Since 
hypertension is more prevalent with increasing age and IVF treated women are older 
than the average pregnant woman, these women should be followed with regular blood 
pressure measurements after end of their pregnancies. A longer follow-up of an IVF 
cohort in the future could give the final answer whether infertile women might be prone 
to develop CVD later in life. 
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9 SVENSK SAMMANFATTNING 
Venös tromboembolism (VTE) är blodproppar i ben eller lungor som orsakas bland 
annat av ett antal ärftliga, livsstils- och miljöfaktorer och där risken att insjukna ökar 
med stigande ålder. Sättet som en blodpropp bildas på är komplext och består av såväl 
blodlevring som aktivering av blodplättar. Blodlevringen skapar ett nätverk av 
fibrintrådar i vilket blodplättarna fastnar och bildar en propp.  
Det kvinnliga könshormonet östrogen ökar risken för att drabbas av blodproppar. 
Under graviditeten stiger nivån av östrogen i blodet och risken för VTE ökar, särskilt i 
den senare delen av graviditeten när östrogennivån är som högst. En av tusen gravida 
kvinnor drabbas av VTE. Blodproppar som fastnar i lungorna kallas lungemboli och är 
den vanligaste dödsorsaken bland gravida kvinnor i västvärlden.  
Syftet med doktorandprojektet var att undersöka om provrörsbefruktning (IVF) gör 
kvinnor mera blodproppsbenägna. Detta studerades både med laboratorietester och 
epidemiologiska studier. Vi undersökte även om hjärtkärlsjukdom är överrepresenterad 
i gruppen kvinnor som fött barn efter IVF jämfört med “vanliga” mödrar från det 
medicinska födelseregistret. 
Jämfört med andra länder har Sverige unika möjligheter att göra epidemiologiska 
studier tack vare de landstäckande hälso- och sjukvårdsregistren. I registren kan man 
identifiera prospektivt insamlade data som kan kopplas till både slutenvårds- och 
öppenvårdsregister med hjälp av personnumret. IVF-registret är ett svenskt 
kvalitetsregister som är knutet till det medicinska födelseregistret, där alla kvinnor som 
fött barn ingår. Med hjälp av dessa register och kopplingen till sluten- och 
öppenvårdsregistret kunde vi identifiera 23 498 kvinnor som genomgått IVF-
behandling under perioden 1990-2008. Bland IVF-behandlade kvinnor var det fyra 
gånger fler som fick VTE och sju gånger fler drabbades av lungemboli under första 
tredjedelen av graviditeten (trimestern) jämfört med 116 960 kontrollkvinnor från det 
medicinska födelseregistret (studie III). Eftersom kvinnor som genomgår IVF är friska, 
unga och blivande föräldrar, är det utomordentligt viktigt att minimera risker med 
behandlingen.  
För att undersöka påverkan av IVF på blodproppsbildning och -upplösning 
(hemostasen) undersökte vi 31 patienter som genomgick IVF. Provtagningen utfördes 
vid två tillfällen; dels vid nedregleringsfasen (låga östrogennivåer) och dels vid 
stimuleringsfasen (höga östrogennivåer). Våra undersökningar fokuserade på metoder 
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som mäter balansen mellan blodproppsbildning och -upplösning (studie II). Genom att 
mäta förmågan till blodlevring hos den enskilda patienten med ett blodprov skulle man 
bättre kunna bedöma om kvinnan har en överrisk för blodproppar under IVF-
behandlingen och den efterföljande graviditeten.  
Vi undersökte även ett ämne från blodkärlen som har samband med proppbenägenhet 
(von Willebrands faktor) och dess reglerande enzym (ADAMTS13) vid samma 
provtagningstider (studie I). Studie I+II visade att kvinnor som genomgått IVF hade en 
generellt högre tendens att bilda blodproppar. 
Infertilitet drabbar cirka 10 procent av alla par i världen. Orsaken till infertilitet kan 
bland annat bero på hormonrubbningar, strukturella hinder hos kvinnan eller nedsatt 
spermakvalitet hos mannen. En stor andel är oförklarad trots omfattande utredning 
vilket bidrar till att tre procent av alla barn i Sverige påbörjar sina liv i ett provrör på 
fertilitetskliniken. 
Vi undersökte vidare om kvinnor som genomgått IVF-behandling hade en ökad 
förekomst av hjärtkärlsjukdomar jämfört med kontrollgruppen (studie IV). Vi följde 
alla kvinnor efter graviditeten från 1990 och fram till slutet av 2009 eller tills de 
drabbades av högt blodtryck, stroke, hjärtinfarkt eller diabetes. Eftersom kvinnorna inte 
hann uppnå så hög ålder under uppföljningsperioden (som var i genomsnitt åtta år) 
fokuserade vi på högt blodtryck, vilket är en av de vanligaste riskfaktorerna för 
hjärtkärlsjukdom och uppträder flera år innan man får en hjärtkärlhändelse. Kvinnorna 
som genomgått IVF-behandling hade en ökad risk att drabbas av högt blodtryck jämfört 
med kontrollgruppen från födelseregistret. Vi såg även en tendens till flera stroke-
insjuknanden i IVF-gruppen.  
Sammanfattningsvis finner vi ett klart samband mellan IVF-behandling och VTE, 
särskilt lungemboli. Detta är särskilt tydligt under de första tre månaderna av 
graviditeten. Vi har också visat att IVF är förenat med störning i blodlevringen. I studie 
IV fann vi ett samband mellan infertilitet och hjärtkärlsjukdom i form av ökad risk att 
utveckla högt blodtryck efter en IVF-graviditet. Om infertilitet och hjärtkärlsjukdom 
har ett samband bör denna patientgrupp följas upp med t.ex. regelbundna 
blodtryckskontroller efter graviditeten så att risken för senare hjärtkärlsjukdom kan 
minimeras.  
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Changes in von Willebrand factor and ADAMTS13 during IVF
Eli Westerlunda, Aleksandra Antovica, Outi Hovattac, Karin P. Ebergc,
Margareta Blomba¨ckd, Ha˚kan Walle´nb and Peter Henrikssonb
During IVF, circulating estradiol concentrations are strongly
increased, and this may have direct effects on hemostasis.
Elevated von Willebrand factor levels represent an
important risk factor for arterial and venous thrombosis.
ADAMTS13, also known as von Willebrand factor-cleaving
protease, has an important regulatory function of von
Willebrand factor but has not been studied during IVF. Blood
was sampled from 31 women at maximal downregulation of
estradiol synthesis using gonadotropin-releasing hormone
analogues and during high-level stimulation of estradiol
synthesis using follicle-stimulating hormone during the first
phase of IVF. Von Willebrand factor antigen, von Willebrand
factor ristocetin cofactor activity, factor VIII and ADAMTS13
antigen and activity levels in plasma were determined at the
time of downregulation and at high-level stimulation.
Estradiol increased from a mean of 154pg/ml at
downregulation to 5889pg/ml at high-level stimulation
(range 1620–19500pg/ml). Factor VIII increased from
0.96W0.34 to 1.26W0.41 kIU/l (P<0.001). Von Willebrand
factor antigen and activity increased from 0.75W0.22 to
1.06W0.40 kIU/l (P<0.001) and from 0.83W0.26 to
1.24W0.48 kIU/l (P<0.001), respectively. ADAMTS13
antigen decreased from 72.2W13.5 to 67.9W9.9% (P<0.05,
PU0.01) and ADAMTS13 activity from 88.6W18.3 to
80.8W15.7% (P<0.01). The increments in estradiol and
factor VIII during IVF were paralleled by an increase in von
Willebrand factor antigen and activity, and a decrease in
circulating ADAMTS13 antigen and activity, respectively.
This could in part explain why these patients have an
increased risk of thrombotic events. Blood Coagul
Fibrinolysis 22:127–131 � 2011 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Introduction
IVF is the most common procedure performed to assist
reproduction. Current studies demonstrate that the pro-
found increase in estrogen attained during IVF exert
direct effects on several hemostatic variables and may
induce a hypercoagulable state [1–3]. The major com-
plication of IVF is the ovarian hyperstimulation syn-
drome (OHSS), which can result in severe arterial or
venous thrombotic complications [4].
The von Willebrand factor (VWF), previously named
factor VIII (FVIII)-related antigen, is an adhesive plasma
glycoprotein synthesized in megakaryocytes and vascular
endothelial cells. It plays a major role in primary hemos-
tasis serving as an adhesive link between platelets and
the damaged vessel wall and indirectly contributes to
coagulation by stabilizing circulating FVIII and protect-
ing it from proteolysis [5]. In response to vascular
damage, VWF is rapidly released in the form of ultralarge
multimers mediating platelet adhesion. An important
regulatory mechanism of VWF levels in plasma is the
activity of a zinc-containing metalloprotease enzyme
ADAMTS13, also known as von Willebrand factor-cleav-
ing protease. This enzyme cleaves VWF at a single site in
the A2 domain, thereby converting ultralarge VWFmulti-
mers into lower molecular weight forms with reduced
adhesive potential [6,7].
Increased circulating levels of VWF have been found in
clinical conditions characterized by endothelial stimu-
lation and dysfunction and are associated with risks of
both arterial and venous thrombosis [8–10]. Both VWF
and FVIII levels raise two-fold to three-fold during the
second and third trimesters of pregnancy [11,12]. IVF
treatment is also associated with an increase in circulating
VWF levels followed by an increase in FVIII levels
[2,13]. Additionally, high plasma concentrations of
VWF have been reported to be of value in predicting
whether patients are at risk of developing severe OHSS
[14], and there is a negative association between plasma
levels of VWF and the activity of ADAMTS13, which
tends to be low in plasma when VWF is high [15–17].
Interestingly, a reduced function of ADAMTS13 is
associated with thrombotic microangiopathies like
thrombotic thrombocytopenic purpura [18–20]. There
are some studies indicating a moderate decrease in this
protease during pregnancy and puerperium [21]. How-
ever, ADAMTS13 has not been investigated previously
in patients undergoing IVF. The present study was aimed
to study possible changes in ADAMTS13 during IVF and
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whether changes in VWF during IVF are related to
changes in ADAMTS13.
Methods
Patients
Thirty-one women undergoing IVF treatment at the
Fertility Unit of Karolinska University Hospital, Hud-
dinge, Sweden, were included in the study.
In order to induce controlled ovarian hyperstimulation,
the estrogen production was first downregulated by using
a gonadotropin-releasing hormone (GnRH) agonist,
buserelin acetate (Suprecur; Aventis Pharma, Mumbai,
India). Starting at the 21st day of menstrual cycle, all
patients received 300mg buserelin acetate three times
per day in the form of nasal spray. After the menstrual
bleeding, 2 weeks later, an estradiol (E2) measurement
was carried out to verify downregulation. Acceptable
baseline hormonal concentration for initiating the IVF
cycle was E2 less than 150 pg/ml. After that, the GnRH
dose was decreased to 300mg twice a day.
Ovarian stimulation was then initiated by using recom-
binant human follicle stimulating hormone (FSH) admi-
nistrated subcutaneously, either as follitropin alpha
(Gonal-f; Merck Serono, Geneva, Switzerland), or as
follitropin beta (Puregon; Schering-Plough, Kenilworth,
New Jersey, USA). The starting dose varied between 75
and 300 IU daily according to the woman’s history and
BMI. The response was followed up by an E2 measure-
ment 6 days later and by ultrasound scanning of the
ovarian follicles at days 9–10 after the first FSH injection.
Blood sampling
Blood samples were taken under fasting conditions twice
during the IVF procedure: the first time at maximal
downregulation of E2 synthesis and the second time
during high-level stimulation (HLS) of E2 synthesis.
Platelet-poor plasma was obtained by centrifugation at
2000g for 20 min and aliquoted plasma samples were
stored at �808C before being analyzed.
Blood tests, such as hemoglobin, platelet cell count,
erythrocyte volume fraction, plasma creatinine and lipids,
and plasma glucose, were performed at the time of the
first blood sampling. Blood pressure, heart rate, weight,
length and waist–hip ratios were also measured. The
patients were interviewed regarding smoking habits and
ongoing medication at inclusion. Patients with polycystic
ovarian syndrome were excluded from the study. The
study was approved by the ethics committee of the
Karolinska Institutet.
Laboratory methods
Von Willebrand factor and factor VIII
Von Willebrand factor antigen (VWF:Ag) concentrations
were measured in plasma using the LIATEST from
Diagnostica Stago (Asnieres, France). The measurement
procedure was according to the manufacturer’s instruc-
tions [22,23]. The von Willebrand factor ristocetin cofac-
tor (VWF:RCoF) activities were measured in plasma
using the BC von Willebrand Reagent from Siemens
Healthcare Diagnostics (Deerfield, Illinois, USA). FVIII
wasmeasured using the COAMATICFVIII reagent from
Haemochrom Diagnostica (Essen, Germany).
ADAMTS13
ADAMTS13 activity and antigen concentrations in
plasma were analyzed using the TECHNOZYM
ADAMTS13 kit which is based on the fluorogenic
method described by Kokame et al. [18]. All reagents
were obtained from Technoclone GmbH (Vienna,
Austria) and their detailed measurement procedure fol-
lowed. Results are reported as the percentage of those of a
pool of plasma from more than 100 healthy donors.
According to the manufacturer, the reference interval
for ADAMTS13 antigen concentration is 75–110% and
for ADAMTS13 activity 50–110% of the pool. The
coefficient of variation (CV%) for duplicates should not
exceed 15% according to the manufacturer. The assay
was run using a Tecan Infinite M220 multireader (Ma¨n-
nedorf, Switzerland).
The uncertainty has been estimated from duplicate
measurements of samples in a recent study performed
at our laboratory and was found to be 10.8% (SD), CV%
9.6, N¼ 48 for ADAMTS13 activity and 6.4% (SD), CV%
7.1, N¼ 48 for ADAMTS13 antigen [24].
Statistical analysis
Statistical analyses were performed using STATISTICA
software, version 8 (Statsoft, Inc., Tulsa, Oklahoma,
USA). We performed parametric tests for normally dis-
tributed variables. Data are presented as mean�SD. E2
concentrations are shown as the mean and the minimal
respectively maximal concentrations (range). P less than
0.05 was considered statistically significant. The analysis
of power in this study was performed a priori based on the
assumption of detecting a 20% difference in the main
endpoint. Our calculations showed that we would need
approximately 16 patients assuming an a of 0.05 and a
power (1�b) of 0.80.
Results
All patients were whites aged 25–38 years and with a
normal resting blood pressure (�140/90mm/Hg). None
of them had a history of venous thrombosis. Basic charac-
teristics of the patients are presented in Table 1.
E2 increased from a mean of 154 pg/ml at downregula-
tion to a mean of 5889 pg/ml at HLS (range 1620–
19 500 pg/ml).
VWF:Ag and VWF:RCoF activity increased by 41 and
49% (P< 0.001) from the time of downregulation to HLS,
respectively. These changes were accompanied by a
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concomitant 6% decrease in ADAMTS13 antigen
(P< 0.05) and a 9% decrease in ADAMTS13 activity
(P< 0.01) (Table 2). The relative changes in
ADAMTS13 antigen and activity from downregulation
to HLS correlated significantly (r¼ 0.7, P< 0.001).
The concentrations of VWF:Ag at HLS were significantly
and inversely correlated to the concentrations of
ADAMTS13 antigen and ADAMTS13 activity at the
same time point (r¼ 0.6, P¼ 0.015 and r¼ 0.5,
P¼ 0.026, respectively).
The FVIII levels increased 31% from the time of down-
regulation to HLS (P< 0.001) (Table 2).
Twelve patients got pregnant and all except one were
primigravida. Three patients developed OHSS. These
three patients had a 64% increased VWF:Ag and 63%
increased VWF:RCoF activity level from the time of
downregulation to the time of HLS. FVIII increased
56% at the same period. These changes were accom-
panied by a 9% decrease in ADAMTS13 antigen and a
14% decrease in ADAMTS13 activity.
Discussion
This is the first report of changes in circulating
ADAMTS13 antigen and activity levels during IVF.
We found increased VWF:Ag and VWF:RCoF activity
together with increased FVIII levels and decreased
ADAMTS13 antigen and activity during the early stage
of the IVF treatment. Furthermore, the concentrations
of VWF:Ag at the time of HLS of E2 production were
inversely correlated to ADAMTS13 antigen and activity
suggesting that changes in ADAMTS13 could partly
influence VWF levels.
E2 levels in plasma changed considerably within a short
period during IVF. Our patients reached on average a
38 times higher E2 level in plasma within a few days after
the start of stimulation. IVF treatment is thus a unique
model to study effects of profound and fast increases in
endogenous estrogen on hemostatic variables.
It has previously been reported that hyperestrogenemia
cause an increase in VWF concentrations in plasma [25].
This is supported by in-vitro findings of Harrison and
McKee, who demonstrated that 17b-estradiol directly
enhanced the synthesis of VWF in endothelial cells in
a dose-dependent manner [26]. It is thus plausible that
the increased level and activity of circulating VWF
observed in the present study are caused by an estrogenic
effect on the vascular endothelium [27].
We found a rapid increase in VWF:Ag and VWF:RCoF
activity levels – at a mean of 45% – in parallel with
increased E2 concentrations during the first few weeks of
IVF. The increase in VWF was smaller than what has
been described during pregnancy [11,12]. However, it has
to be considered that our measurements were performed
within only a few days after the initiation of estrogen
stimulation and starting from very low levels of E2
attained during the preceding phase of downregulation.
By contrast, the VWF levels during pregnancy were
assessed after long-term stimulation by high levels of
estrogens in the third trimester of pregnancy. Moreover,
the variability between separate individuals with respect
to increments in VWF following stimulated estrogen
production is considerable.
It is not possible to deduce whether the observed changes
in plasma levels of VWF could influence the develop-
ment of OHSS in this particular group of patients. It is
however known that an acute rise in VWF during the first
48 h of the acute coronary syndrome is a significant
predictor of adverse cardiovascular events during the
following 14 respectively 30 days [10].
Moreover, VWF contributes to coagulation by stabilizing
FVIII, which is an essential blood-clotting factor. A high
plasma level of FVIII is a risk factor for venous throm-
boembolism [28,29]. In our study, the rise in FVIII
concentration by 31% is similar to that previously
reported by Bremme et al. [2] in patients undergoing
IVF, suggesting the presence of a procoagulant state
during the course of ovarian stimulation. Still, as the
concentrations of VWF and FVIII are strongly related,
it may be difficult to unravel separate effects of these
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Table 1 Baseline characteristics of the 31 women enrolled in the
study
Patients Normal range
Age (years) 33.0�3.3
BMI (kg/m2) 24.1�3.6 <25
Waist–hip ratio 0.8�0.1 <0.8
Causes and type of infertility
Female [n (%)] 7 (22.6)
Male [n (%)] 12 (38.7)
Unknown [n (%)] 12 (38.7)
Current smoking [n (%)] 2 (11.1)
Triglycerides (mmol/l) 0.8�0.4 0.45–2.6
Total cholesterol (mmol/l) 4.9�0.7 3.3–6.9
LDL cholesterol (mmol/l) 2.9�0.7 1.4–4.7
Creatinine (mmol/l) 68.9�7.3 <90
Blood sugar (mmol/l) 4.7�0.5 4.0–6.0
Hemoglobin (g/l) 129.0�8.6 117–153
Hematocrit (%) 0.39�0.02 0.35–0.46
Platelet count (�109 per l) 251.2�47.6 165–387
Data are presented as mean�SD or n (%). LDL, low-density lipoprotein.
Table 2 Changes in von Willebrand factor, ADAMTS13 and factor
VIII during IVF
Downregulation High-level stimulation P
VWF:Ag activity (kIU/l) 0.75�0.22 1.06�0.40 <0.001
VWF:RCoF activity (kIU/l) 0.83�0.26 1.24�0.48 <0.001
ADAMTS13 antigen (%) 72.2�13.5 67.9�9.9 <0.05
ADAMTS13 activity (%) 88.6�18.3 80.8�15.7 <0.01
Factor VIII (kIU/l) 0.96�0.34 1.26�0.41 <0.001
Data are presented as mean�SD; n¼31. Percentage¼percentage of normal
pooled plasma. VWF:Ag, Von Willebrand factor antigen; VWF:RCoF, von Will-
ebrand factor ristocetin cofactor.
proteins on a possible development of a hypercoagulable
state during IVF.
There is until now limited knowledge of effects of sex
hormone on ADAMTS13 levels. In normal pregnancy,
Mannucci et al. [30] have described a 32% decrease in
ADAMTS13 activity levels in the second and third
trimester. Thus, the authors suggested that estrogen
could be one of the regulators of ADAMTS13 activity
in plasma. In our study, we analyzed both ADAMTS13
antigen and activity in plasma, and our data clearly show
that not only the antigen concentration of ADAMTS13
but also the activity of this enzyme was reduced during
the extremely increased estrogen levels in this phase of
IVF. Measuring both ADAMTS13 antigen and activity
helps us to understand whether or not the protease is fully
active and provides a new tool for understanding the
physiology and pathophysiology of ADAMTS13 [31].
Our results support the idea that estrogen is of import-
ance in the regulation of ADAMTS13 levels.
We also observed a significant inverse relationship
between VWF:Ag and ADAMTS13 antigen and activity
at the time ofHLSwith a correlation coefficient of around
0.5. We can thus assume that approximately 25% of the
variability in VWF level in this study could be explained
by changes in the levels of ADAMTS13. Clearly, other
estrogen-related mechanisms, such as a direct effect on
endothelial cells, may also be active in the regulation of
the VWF levels observed during IVF [27].
In the present study, three patients developed OHSS.
This is an occasional iatrogenic complication of ovarian
stimulation usually occurring several days after embryo
transfer. Clinical manifestations are massive extravascu-
lar fluid accumulation and hemoconcentration which
appears to be caused by increased capillary permeability
in the vascular endothelial cells. Mild cases of OHSS has
been reported in up to 25% of the women undergoing
IVF [32], and it is estimated that one out of 128 women
with severe OHSS develop thromboembolic disease [33].
High plasma concentrations of VWF were found to be of
value in predicting a risk of severe OHSS [14]. Ogawa
et al. [4] demonstrated that the plasma levels of VWF
exhibited a significant rise before the development of
clinical manifestations of moderate to severe OHSS, and
that the magnitude of the rise was associated with the
clinical severity of OHSS. In our three patients who
developedOHSS, there seemed to be amore pronounced
increase in VWF:Ag and FVIII levels (mean increase of
64 and 56%, respectively) from downregulation toHLS as
compared in the patients without the OHSS (mean
increase of 45 and 31%, respectively). Furthermore,
ADAMTS13 antigen and activity levels in these three
patients decreased to a larger extent than in the patients
without OHSS. However, it remains unclear whether this
pronounced decrease in ADAMTS13 levels in patients
with OHSS was due to inhibition of its enzymatic
activity, consumption of the protease or increased clear-
ance from plasma.
To conclude, decreased circulating levels of ADAMTS13
together with a functional failure of this enzyme might
result in higher levels of VWF and thus affect hemostasis
in patients undergoing IVF. Further research is needed to
increase the understanding of a possible pathophysiolo-
gical role of ADAMTS13 in thrombosis. Furthermore,
additional experimental studies are needed to elucidate
the effects of estrogens on ADAMTS13.
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Introduction: Controlled ovarian hyperstimulation during in vitro fertilization (IVF) causes profound incre-
ments in serum estradiol which may inﬂuence haemostasis and the ovarian hyperstimulation syndrome.
In the present study we investigated the effect of the standard IVF-stimulation protocol on coagulation and
ﬁbrinolysis as assessed by different global haemostatic assays.
Materials and Methods: Blood samples were drawn from 31 women during the down-regulation phase when
estradiol secretion is inhibited, and before egg retrieval, i.e. when estradiol levels are at supraphysiological
levels, in the following called high level stimulation phase. Haemostasis was assessed during both treatment
phases with 1) the calibrated automated thrombogram which measures thrombin generation, 2) overall hae-
mostasis potential which measures ﬁbrin formation and degradation and 3) ﬁbrin gel permeability measure-
ments which measures the quality of the ﬁbrin network.
Results: Estradiol increased from b150 pg/mL to 5889 pg/mL (range 1620–19500 pg/mL). We found both in-
creased thrombin generation as measured by the calibrated automated thrombogram (pb0.001) and an in-
crease in overall haemostasis potential (pb0.001) from time of down-regulation to high level stimulation.
Conclusions: The assays used indicated procoagulable changes in haemostasis during in vitro fertilization.
Further studies should evaluate their potential in the prediction of thrombosis and hyperstimulation.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Controlled ovarian hyperstimulation for in vitro fertilization (IVF)
is a routine procedure in infertility treatment. A major complication
of IVF is the ovarian hyperstimulation syndrome (OHSS) which has
been associated with arterial and venous thrombotic complications
in severe cases [1]. Precise ﬁgures of incidence are unknown because
of lack of a systematic registration. Mild OHSS probably occurs in 8-
23% of stimulated cycles, moderate forms in b1-7% and severe forms
in ~0.5% of stimulated cycles [2,3]. High serum estrogen concentra-
tions and an increased number of small ovarian follicles at the time
of ovulation induction are factors known to relate to the development
of OHSS, but the predictive value of these factors for the development
of OHSS is not high [4,5].
Previous studies demonstrate that supraphysiological increases in
estrogen during IVF exert direct effects on individual haemostatic
variables [6–9] and may induce a procoagulable state. Still, very little
is known about the effects of short-term alterations of endogenous
estrogen concentration during IVF treatment on the overall haemo-
static balance of the individual. Although there is a wide spectrum
of recently developed global haemostatic assays, none of them has
so far been used to assess changes during IVF.
The calibrated automated thrombography (CAT) assay is a com-
mercially available global haemostatic method which determines
the time integral of thrombin generation after triggering with tissue
factor, called endogenous thrombin potential (ETP) [10]. The CAT
assay is based on the assumption that thrombin generation in exam-
ined plasma reﬂects the sum of the activities and concentrations of
pro- and anticoagulant substances. An increasing body of evidence
shows that CAT may be a useful tool in the diagnosis of acquired or
congenital procoagulable states and is sensitive enough to detect
some forms of hemorrhagic diathesis [11,12].
In contrast to CAT which is used to screen thrombin generation in
the examined plasma, and thereby coagulation capacity only, we have
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developed the Overall Haemostasis Potential assay (OHP) [13] as a
quantitative method for determination of the ﬁbrin level in plasma
associated with combined potential of coagulation and ﬁbrinolysis.
It is based on repeated spectrophotometric registrations of ﬁbrin-
aggregation in citrated plasma, to which small amounts of exogenous
thrombin, t-PA and CaCl2 have been added. Our previous investiga-
tions have shown that this approach can be used to detect a variety
of procoagulable disorders [13–15] as well as hypocoagulability due
to deﬁciencies of procoagulants [14,16].
Moreover, by using the liquid-permeation technique to investi-
gate ﬁbrin gel permeability [17–19], the quality of the ﬁbrin clot can
be studied. The permeability coefﬁcient (Ks) is an established param-
eter that provides information on the overall clot structure and re-
ﬂects the size and shape of the pores in the clot. Low value of Ks
indicates a tighter, less porous ﬁbrin clot, which is more resistant to
ﬁbrinolysis [20] and may be associated with thrombotic complica-
tions [21,22].
The individual coagulation factors i.e. ﬁbrinogen and FVIII are
known to increase during IVF [4] and were also investigated. More-
over, these coagulation factors are known to correlate to the variables
of the above mentioned global haemostasis assays [10,13] which sup-
ported their assessment in the present study.
The aim of the present study was to evaluate the effects of the
standard IVF-stimulation protocol on coagulation and ﬁbrinolysis as
assessed by different global haemostatic assays The effects of the
IVF stimulation protocol on the ﬁnal events in coagulation, i.e. the for-
mation of a ﬁbrin network, were investigated by studying the perme-
ability of the ﬁbrin gel.
Material and methods
Subjects
The present study was approved by the Regional Ethics Commit-
tee of the Karolinska Institutet and all participants gave their in-
formed consent. Thirty-one consecutive women undergoing IVF
treatment at the Fertility Unit of Karolinska University Hospital, Hud-
dinge, were included in the study. At inclusion patients were inter-
viewed regarding smoking habits, ongoing medication and own or
family history of venous thrombotic diseases, diabetes and cardiovas-
cular diseases. All patients were Caucasian aged 25–38 years (mean±
SD=33±3.3) and none of them suffered from arterial hypertension,
diabetes mellitus, dyslipidaemia, or had a history of arterial or venous
thromboses. Patients with polycystic ovarian syndrome or ongoing
anticoagulation treatment were excluded from the study.
In order to induce controlled ovarian hyper-stimulation, the estro-
gen production was ﬁrst down-regulated by using a gonadotrophin
releasing hormone agonist, Buserelin® (Suprecur, Aventis Pharma,
Frankfurt, Germany). Starting on the 21st day of menstrual cycle all
patients received 300 μg Buserelin® three times per day in a form of
nasal spray. After the menstrual bleeding, two weeks later, an estradi-
ol (E2) measurement was carried out to verify the down-regulation.
Acceptable baseline hormonal concentration for initiating the IVF
cycle was E2 b150 pg/ml. After that, the GnRH dose was decreased
to 300 μg twice a day.
The ovarian stimulation was then initiated by using recombinant
human Follicular Stimulating Hormone administrated subcutaneous-
ly, either as follitropin alpha (Gonal-f, Merck Serono, Stockholm, Swe-
den), or as follitropin beta (Puregon, Schering-Plough, Gothenburg,
Sweden). The starting dose varied between 75 and 300 IU daily
according to the woman's history and body mass index. The response
was followed up by an E2 measurement six days later, and by ultra-
sound scanning of the ovarian follicles at days 9–10 after the ﬁrst
FSH injection. It was repeated when necessary.
The trans-vaginal ultrasound-guided oocyte retrieval was planned
when the largest follicles had reached the diameter of 18 mm. At that
stage, 250 μg human recombinant chorion gonadotrophin, (Ovitrelle,
Merck-Serono) or 5000–10 000 IU urine-puriﬁed human chorion go-
nadotrophin (Pregnyl, Schering-Plough) were given to induce the
ﬁnal maturation of the oocytes, which were retrieved 36–38 hours
later. Therefore, the oocytes were retrieved 10 to 14 days after
starting the Follicular Stimulating Hormone stimulation.
Blood sampling
Blood samples were taken under fasting conditions twice during
the IVF procedure: the ﬁrst time at maximal down-regulation (DR)
of E2 synthesis (b150 pg/mL) and the second time during high level
stimulation (HLS) of E2 synthesis before hCG is given. Blood samples
were taken by venipuncture in a buffered sodium citrate medium (9
parts blood+1 part sodium citrate, 0.129 mol/L; pH 7.4). Platelet-
poor plasma was obtained by centrifugation at 2000 g for 20 minutes
at room temperature, and plasma aliquotes were stored at −80 °C.
At the time of the ﬁrst blood sampling we measured whole blood
haemoglobin concentrations, platelet counts and white blood cell
counts in venous blood, hematocrit, serum creatinine, sodium, potas-
sium, CRP and liver transaminases in plasma, as well as plasma glu-
cose concentrations.
Laboratory methods
Endogenous Thrombin Potential
The CAT assay was performed essentially as described by Hemker et
al. [10] and according to the manual provided by Thrombinoscope B.V.
(Maastricht, the Netherlands). Coagulation is initiated by recalciﬁcation
in the presence of 5 pM tissue factor and 4 μM phospholipids and
thrombin generation is continuously registered by measuring cleavage
of a ﬂuorogenic substrate. Four parameters were derived from the
thrombin generation curves: lag time (initiation phase of thrombin
generation), ETP (thrombin formation over time which is measured
as “area under the curve”), peak height (i.e. peak thrombin concentra-
tion) and time to peak (i.e. time to peak thrombin concentration). The
lag time was deﬁned as the time to reach one-sixth of the peak height.
The time until the thrombin concentration peak is reached, is described
as the time to peak. The area under the curve (ETP) represents the total
amount of thrombin generated over time.
Determination of Overall Haemostatic Potential (OHP) in plasma
The OHP assay is based on repeated spectrophotometric registra-
tion of ﬁbrin-aggregation in citrated plasma, to which small amounts
of exogenous thrombin, t-PA and CaCl2 have been added [23]. For the
overall coagulation potential (OCP), CaCl2 (ﬁnal concentration
35 mmol/l) and thrombin (ﬁnal conc. 0.09 IU/mL) were added to
Tris buffer (66 mmol/l Tris and 130 mmol/l NaCl, pH 7). For OHP, t-
PA (ﬁnal conc. 660 ng/mL) was also added to the buffer for OCP. Sev-
enty μL of plasma in each well of the microplate (NUNC, USA) were
mixed with 10 μl of platelet reagent (Unicorn Diagnostics Ltd, London
UK), which is a platelet membrane preparation derived from washed
normal human platelets (106 mL-1). After that, 50 μL of the buffer for
determination of OCP or OHP, respectively, was added (ﬁnal conc. of
CaCl2 17 mmol/l and thrombin 0.04 IU/mL in both plus t-PA 300 ng/
mL in the latter). Absorbance (Abs) at 405 nm was measured each
minute for 40 min to construct the two ﬁbrin-aggregation curves,
OCP and OHP. The area under the curve was expressed by a summa-
tion of the Abs values (Abs-sum). The difference between the two
areas reﬂects the overall ﬁbrinolysis potential (OFP), calculated by
OFP (%)=((OCP-OHP)/OCP)×100.
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Flow measurement for determining ﬁbrin gel permeability
As previously described [20], the ﬁbrin gels were prepared by
adding a 10 μl TRIS buffer containing 0.42 mol/l CaCl2 and 8.3 IU/ml
thrombin, giving ﬁnal concentrations of 20 mmol/l and 0.4 IU/ml, re-
spectively, to 200 μL dialyzed plasma in a small plastic cylinder
(2.5 cm long, opening area 0.1 cm2). The cylinder containing the ﬁ-
brin gel was kept in a standing position in a wet box at room temper-
ature overnight. Permeability (porosity) of the gel was measured by
the volume of a buffer (pH 7.4, 0.02 mol/L TRIS, 0.02 mol/L imidazol,
0.1 mol/L NaCl) percolated through the gel under different hydrostat-
ic pressures. We measured the eluted amount of buffer obtained with
respective pressure and calculated the permeability coefﬁcient (Ks)
using a special equation given by Carr et al. 1977 [24].
FVIII was measured using the COAMATIC FVIII reagent from Hae-
mochrom Diagnostica (Essen, Germany). Fibrinogen was analysed
by Fibri-Prest Automate from Diagnostica Stago (Asnieres, France).
Statistical analysis
Statistical analyses were performed by parametric tests for nor-
mally distributed variables. Non-normal distributed data were log-
transformed and checked to be normally distributed before analysis.
Association was estimated by determining regression coefﬁcients
and correlations of variables with a normal distribution. Multiple re-
gression was used when there was more than one independent vari-
able. Data are presented as mean±SD. Pb0.05 was considered
statistically signiﬁcant. The inter- and intra-assay CVs for all tests
were less than 10 [20,25]. The analysis of power in this study was per-
formed a priori based on the assumption to detect a 20% difference in
both the endpoints ETP respectively OHP. Our calculations showed
that we would need approximately 16 patients assuming an α error
of 0.05, to achieve a power (1-ß) of 0.80.
Results
Basic characteristics of the investigated subjects are presented in
Table 1.
E2 increased from b150 pg/mL at DR to 5889±4723 pg/ml at HLS
(range 1620–19500). Fibrinogen and FVIII concentrations in plasma
increased by 19% (pb0.001) and 30% (pb0.001) from time of DR to
HLS. We observed a 32% increase in OHP (pb0.001) and a 27% in-
crease in OCP (pb0.001) whereas OFP remained almost unchanged
(a non signiﬁcant decrease by 1.5% from time of DR to HLS was ob-
served). Of the thrombin generation variables ETP (pb0.001) and
peak height (pb0.001) were signiﬁcantly raised at HLS as compared
to DR. Concurrently there were decreases in lag time (p=0.001)
and time to peak (pb0.001). The levels of ETP, peak height and time
to peak in all 31 patients are shown in Fig. 1. Regarding ﬁbrin gel per-
meability only a small (−9%) statistically non-signiﬁcant reduction in
permeability (Ks) was observed (p=0.13).
Although signiﬁcant changes toward increased coagulation were
observed in the variables of thrombin generation as well as ﬁbrin for-
mation, all remained within normal limits (Table 2). The signiﬁcant
results remained also after exclusion of the three patients who later
developed OHSS. All changes in haemostasis variables during IVF
are shown in Table 2.
The changes in E2 correlated negatively to the change in lagtime
(r=−0.49, p=0.005) and the change in time to peak (r=−0.47,
p=0.008). At HLS E2 correlated to peak height (r=0.40, p=0.026).
There were no other relations between E2 and the global haemostatic
markers.
Multiple regression analyses showed that the change in FVIII from
DR to HLS explained a part of the change in OHP (r=0.49, p=0.024).
The change in peak height could in part be explained by the change in
ﬁbrinogen and FVIII (r=0.47, p=0.034).
Multiple regression analyses performed at the time of HLS showed
that plasma ﬁbrinogen signiﬁcantly explained a part of the variation
in OHP (overall haemostatic potential) (r=0.65, p=0.002). In addi-
tion to ﬁbrinogen ETP also explained a part of the variation in OCP
(r=0.70, pb0.001). Fibrinogen and FVIII explained a part of the var-
iation of peak height (r=0.47, p=0.031).
We found a strong correlation between ETP and peak thrombin
height both at the time of DR and HLS (r=0.85, pb0.001 and
r=0.80, pb0.001 respectively).
Twelve patients got pregnant and all except one were primigravidae.
Three patients suffered amild OHSS as deﬁned by the Practice Com-
mittee of the American Society for Reproductive Medicine [26]. They
had higher mean levels of ETP, OHP and ﬁbrin gel permeability than
those without OHSS; however, conventional statistical tests were not
performed due to the low number of cases.
Discussion
This is, to the best of our knowledge, the ﬁrst study in which the
global haemostatic methods CAT, OHP and the ﬁbrin clot permeability
assay have been investigated and compared during IVF treatment. We
were able to demonstrate a highly signiﬁcant increase in ETP and OHP
concomitant with an approximately 38 times increase in estradiol from
time of DR to HLS. It thus seems that elevations in circulating estrogens
during IVF cause a shift in the haemostatic balance in the direction of a
procoagulable state. It is tempting to speculate that this change may
confer an increased risk of thromboembolic complications.
IVF pretreatment is a unique model to study the effect of estrogen
on haemostasis because endogenous estrogen levels change consider-
ably within a short period of time. At the same time the mechanisms
by which estrogen induces changes in haemostatic variables can be
examined in a controlled manner during IVF, in contrast to studies
with wide variations of estrogen dosages, routes of administration
and patient populations.
The studies of individual coagulation factors disclose a clear in-
crease in VWF, Factors VIII, V, ﬁbrinogen, as well as increased APC re-
sistance, together with reduced AT, proteins C and S activity when
ovarian stimulation occurs [7,9,27–29]. Our results, showing in-
creased levels of FVIII and ﬁbrinogen during IVF are therefore not sur-
prising. In addition, some markers reﬂecting ﬁbrinolysis are reduced
during IVF [30–32]. The recently published study by our group
brought to knowledge that even reduced levels of ADAMTS13 antigen
and activity contribute to the increased levels of VWF at the time of
HLS [33]. Totally, the individual factors seem to change towards a
hypercoagulable state during IVF.
Although several reports have highlighted a need for more rapid
testing as an aid in the diagnosis and treatment of OHSS and thrombotic
Table 1
Baseline characteristics of the 31 patients.
Patients Reference interval
Age, years 33.0±3.3
Body mass index, kg/m² 24.1±3.6 b25
Waist-hip ratio 0.8±0.1 b0.8
Causes and type of infertility
Female, n (%) 7 (22%)
Male, n (%) 12 (39%)
Unknown, n (%) 12 (39%)
Current smoking, n (%) 2 (11%)
Triglycerides, mmol/l 0.8±0.4 0.45-2.6
Total cholesterol, mmol/l 4.9±0.7 3.3-6.9
LDL cholesterol, mmol/l 2.9±0.7 1.4-4.7
Creatinine, mmol/l 68.9±7.3 b90
Blood glucose, mmol/l 4.7±0.5 4.0-6.0
Hemoglobin, g/L 129.0±8.6 117-153
Hematocrit, % 0.39±0.02 0.35-0.46
Platelet count, x109 /L 251.2±47.6 165-387
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diseases following IVF, only a limited number of haemostatic markers
have been evaluated in individuals who eventually develop this compli-
cation [34]. Many of these tests are complicated, costly, and not widely
available. To our knowledge, the study by Harnett et al. [35] was the
only one utilizing a global haemostasis assay in IVF patients. They
used thromboelastography in whole blood samples from 24 women
at the time of down regulation and at the time of oocyte retrieval. A sig-
niﬁcant decrease in clot formation time and an increase in clotting
index at the time of oocyte retrieval, indicated that supraphysiologic es-
trogen levels during IVF pretreatment were associated with a signiﬁ-
cant increase of the coagulable state. Aligning these ﬁndings, our
results demonstrate that isolated high estrogen concentrations, as pro-
duced by an IVF protocol, are associated with an overall increase in
haemostatic capacity.
Thrombin generation is augmented during IVF as demonstrated by
the increase in both ETP and peak height, together with a decreased
time to thrombin generation (lag phase) and time to peak of thrombin
generation. A similar pattern has been observedwhen these parameters
were analyzed in relation to the increased estrogen levels during nor-
mal pregnancy [36], preeclampsia [37] and oral contraceptive use [38].
Previous studies by our group have conﬁrmed the sensitivity of
the OHP method to detect the presence of a procoagulable state
when circulating estrogen levels are elevated. Along with increased
gestational age in pregnant women OHP and OCP increased and OFP
decreased [13]. Furthermore, hormone replacement treatment with
high-dose oral estrogen in postmenopausal women caused an activa-
tion of coagulation and a decrease in ﬁbrinolysis as measured by the
OHP assay [39]. During controlled ovarian hyperstimulation in the
present study, OHP increased signiﬁcantly from the time of DR to
HSL. Change in OHP was partly determined by change in FVIII level,
as demonstrated by a statistically signiﬁcant correlation between
OHP on one side and the concentration of this coagulation protein
on the other side. An additional variable of this global haemostatic
assay - the Overall Coagulation Potential (OCP) - was signiﬁcantly in-
creased and correlated to ETP levels at the time of HLS reﬂecting en-
hanced thrombin generation in the IVF patients.
The studies of ﬁbrinolysis parameters during IVF are quite oppos-
ing demonstrating a down-regulation of ﬁbrinolysis at the time of oo-
cyte retrieval on one side [27,30], as well as a ﬁbrinolysis activation,
with increased plasmin-antiplasmin (PAP) complexes and decreased
PAI-1 on the other side [40]. The overall ﬁbrinolysis potential (OFP)
investigated in the present study was not signiﬁcantly altered during
IVF procedure, remaining within the reference range both at DR and
HLS. It is possible that sample collection, preparation, and testing mo-
dality explained this difference. Still, our results demonstrate that
supraphysiological estrogen levels during IVF exert more pronounced
effects on coagulation than on ﬁbrinolytic system, as observed by in-
vestigated global haemostatic markers.
A slight and non-signiﬁcant decrease in ﬁbrin gel permeability
(Ks) was observed following HLS. This may be somewhat surprising
as increased thrombin generationmay be expected to induce a tighter
and more stable ﬁbrin clot. However, we used a relatively high concen-
tration of thrombin to initiate clot-formation in our assay so endoge-
nous thrombin generation should not inﬂuence the characteristics of
the ﬁbrin network formed. The observed increase in ﬁbrinogen concen-
tration observed, could only partly inﬂuence the results of ﬁbrin clot
permeability. Fibrin polymerisation rate as well as altered levels of
ﬁbrinogen-binding proteins (such as FXIII) are additional mechanisms
that may affect ﬁbrin clot porosity and deserve further investigations.
Despite the signiﬁcant alterations in most of the investigated pa-
rameters in our study pointing towards enhanced coagulation, it
Fig. 1. Changes in ETP, Peak and Time to Peak in 31 patients.
Table 2
Plasma levels of haemostatic markers during the IVF treatment.
DR HLS p-level Reference interval
Factor VIII, % 1.0±0.3 1.3±0.4 b0.001 0.5 – 1.5
Fibrinogen, g/L 2.8±0.7 3.3±0.7 b0.001 2 – 4
Fibrin gel permeability, Ks 9.5±3.5 8.6±3.0 0.13 9.3 – 11.1
OHP, Abs sum 7.7±2.9 10.2±3.4 b0.001 4.2 – 14.5
OCP, Abs sum 15.3±5.4 19.5±5.5 b0.001 6.8 – 20.0
OFP, Abs sum 48.2±11.7 47.5±11.8 0.75 16.5 – 52.0
ETP, nM IIa 1542±287 1739±288 b0.001 1430 – 2273
Lag time, min 2.7±0.6 2.5±0.5 0.001 2.1 – 2.9
Peak, nM IIa 290±42 343±38 b0.001 270 – 395
ttPeak, min 5.3±0.7 4.8±0.6 b0.001 4.4 – 5.7
DR=down regulation.
HLS=high level stimulation.
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cannot be neglected that all variables remained within reference
ranges. Nevertheless, there are potential scientiﬁc as well as clinical
implications of our results. To start with, this is the ﬁrst study of
CAT and OHP parameters as well as ﬁbrin clot permeability in this
group of patients establishing reference intervals of these parameters
which could differentiate them from normal pregnant women or
patients treated with exogenous estrogens. More importantly, all in-
vestigated patients were healthy women without previous thrombo-
embolic events or known thrombophilia and all of them underwent
infertility treatment with the most widely accepted technique. Our
results demonstrate that supraphysiologic estrogen concentrations
gained during this treatment are associated with signiﬁcant increases
in the coagulable state which potentially could lead to thrombotic
complications that can markedly affect the quality of life of these
women. However, further experimental and prospective clinical stud-
ies are needed to establish the relevance of ETP and OHP as risk pre-
dictors of future thrombotic events and as tools to monitor the IVF
treatment.
In conclusion, supraphysiologic estradiol concentrations during
IVF-induced ovarian stimulation can lead to alteration of overall
haemostasis towards a procoagulable state as demonstrated by global
haemostatic markers and are related to increased thrombin genera-
tion and ﬁbrin formation rather than decreased ﬁbrinolysis or alter-
ations in ﬁbrin network characteristics.
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Abstract
Objective To estimate the risk of pulmonary embolism and venous
thromboembolism in pregnant women after in vitro fertilisation.
Design Cross sectional study.
Setting Sweden.
Participants 23 498 women who had given birth after in vitro fertilisation
between 1990 and 2008 and 116 960 individually matched women with
natural pregnancies.
Main outcome measures Risk of pulmonary embolism and venous
thromboembolism (identified by linkage to the Swedish national patient
register) during the whole pregnancy and by trimester.
Results Venous thromboembolism occurred in 4.2/1000 women (n=99)
after in vitro fertilisation compared with 2.5/1000 (n=291) in women with
natural pregnancies (hazard ratio 1.77, 95% confidence interval 1.41 to
2.23). The risk of venous thromboembolism was increased during the
whole pregnancy (P<0.001) and differed between the trimesters
(P=0.002). The risk was particularly increased during the first trimester,
at 1.5/1000 after in vitro fertilisation versus 0.3/1000 (hazard ratio 4.22,
2.46 to 7.26). The proportion of women experiencing pulmonary
embolism during the first trimester was 3.0/10 000 after in vitro fertilisation
versus 0.4/10 000 (hazard ratio 6.97, 2.21 to 21.96).
Conclusions In vitro fertilisation is associated with an increased risk of
pulmonary embolism and venous thromboembolism during the first
trimester. The risk of pulmonary embolism is low in absolute terms but
because the condition is a leading cause of maternal mortality and clinical
suspicion is critical for diagnosis, an awareness of this risk is important.
Trial registration ClinicalTrials.gov NCT01524393.
Introduction
Infertility affects more than 10% of couples worldwide.1 Since
the birth of the first “test tube baby” in 1978, in vitro fertilisation
has been used increasingly to assist reproduction.2 To date about
five million people have been born after in vitro fertilisation
and this method is regarded as an effective and safe technique,
with about a third of attempts resulting in pregnancy and a
quarter in live births.3 4
It is well known that the risk of venous thromboembolism is
increased during normal pregnancy. According to data from
Sweden and Norway during the early 1990s venous
thromboembolism occurred in slightly more than one out of
1000 pregnant women.5 6 Venous thromboembolism in pregnant
women after in vitro fertilisation has been reported in numerous
case reports and in two small consecutive series, two out of
2500 (0.8/1000)7 women and three out of 2748 (1.1/1000)
women.8 Notably, these estimates of incidence have been
claimed to be comparable to those during natural pregnancy.9
A recent report suggested that the incidence of venous
thromboembolism after in vitro fertilisation was substantially
increased during the first trimester but not in the other two
trimesters.10 No information exists on the risk of pulmonary
embolism after in vitro fertilisation, which is important because
embolism is a leading cause of maternal mortality.11 12 Moreover,
in the recently published report outpatient diagnoses were not
included and no adjustments were made for the increased
incidence of venous thromboembolism during the past decade.10
Furthermore, no adjustments were made for the reported age
difference in cases and controls, making the strength of the risk
estimate of a 10-fold increase during the first trimester less
exact.
We compared the risk of pulmonary embolism and venous
thromboembolism in pregnant women after in vitro fertilisation
with that of age and time matched women with natural
pregnancy.
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Methods
This cross sectional study was based on the Swedish population
between 1990 and 2008, with linkage of data from two national
registers. The Swedish national patient register encompasses
both inpatients and outpatients.13 Inpatient data in Sweden
became available nationwide in 1987. Outpatient diagnoses
from hospitals started to be collected in 1997. Data in the patient
register can be linked to other registries through the unique
personal identity number assigned to Swedish residents.14
Women who underwent in vitro fertilisation
From the Swedish in vitro fertilisation register at the National
Board of Health and Welfare we retrieved information on
mothers who had given birth after in vitro fertilisation. This
register is now part of the Swedish medical birth register at the
National Board of Health andWelfare and includes information
on pregnancies after in vitro fertilisation since 1982. The birth
register includes data that were collected and registered at the
time the women were pregnant and includes validated
information on the pregnancy, delivery, and neonatal periods
for more than 99% of births in Sweden since 1973.15 The birth
register does not, however, include data onmiscarriages or other
pregnancy losses.
We restricted data retrieval to mothers of children born from
1990 and whose first child was born after assisted reproduction
by in vitro fertilisation. Subsequent pregnancies in these women
were therefore excluded from the study. Thus we identified 23
498 women who had given birth to their first child after in vitro
fertilisation between 1990 and 2008.
Women who did not undergo in vitro
fertilisation
From themedical birth register each womanwho had undergone
in vitro fertilisation was matched with up to five women whose
first child was born without in vitro fertilisation by calendar
year of delivery (two years either way) and maternal age (one
year either way). Subsequent pregnancies in these women were
excluded from the study; the analysis therefore included only
one pregnancy per patient. The matching resulted in 116 960
women who did not undergo in vitro fertilisation.
From the medical birth register we retrieved information on the
women’s country of birth, body mass index before pregnancy,
marital status, smoking status, number of older siblings,
singleton or multiple births, and estimated length of gestation.
We calculated the dates of the trimesters from the length of
gestation. The women’s level of educational attainment was
obtained from the register of education, Statistics Sweden, by
record linkage.14
We obtained information on the diagnoses of venous
thromboembolism including pulmonary embolism by linkage
to the Swedish patient register.13 The register comprises date of
admission and discharge and the main diagnosis, with up to
seven concomitant diagnoses. Inpatient care has been recorded
nationwide since 1987. Outpatient visits at specialist clinics are
included from 1997. Diagnoses were recorded according to the
International Classification of Diseases (ninth revision before
1996 and 10th revision from 1997): codes 415B, 451B, 452,
453C-D, 453W, 453X, 673C, 671D-E, and 671F in ICD9 and
I260, I269, I801-3, I808-9, I822-3, I828-9, O223, O225, O871,
O873, O879, and O882 in ICD10. We therefore included all
possible diagnoses of venous thromboembolism irrespective of
location.
Statistical analysis
The risk of venous thromboembolism and pulmonary embolism
was assessed in womenwho had and had not undergone in vitro
fertilisation during three periods: from 1 January 1987 to the
calculated date of start of pregnancy, during pregnancy and
delivery plus 42 days, and from day 43 to day 365 after delivery.
We calculated proportional hazard regression on time to first
event. To model and test the effect of in vitro fertilisation on
venous thromboembolism in the different trimesters and delivery
we used time dependent proportional hazard regression. We
calculated 95% confidence intervals. In the time dependent
model we tested effect modification of body mass index on the
effect of in vitro fertilisation.Multivariate analysis taking parity,
single or multiple births, smoking, education, maternal age,
country of birth, calendar period, and marital status into account
was carried out on the material stratified on body mass index
and restricted to women with a body mass index <30.
All statistical calculations were done using SAS software,
version 9.3. The regressions were carried out in the proportional
hazards regression (PHREG) procedure of SAS.
Results
Overall, 23 498 women were identified who had given birth
after in vitro fertilisation. The median age of these mothers was
33 (interquartile range 31-36) years. Matching with womenwho
had not had in vitro fertilisation resulted in an almost identical
age distribution (median 33 (31-36) years, table 1⇓). The
proportion of multiple births in the women who had undergone
in vitro fertilisation was 16.9%. Of the women who had had in
vitro fertilisation about 86% were born in Sweden, 6.7% were
smokers, 53.2% had a body mass index <25, 8.1% were obese
(bodymass index >30), and 47.1% had attained university level
education (>12 years).
The proportion of women who underwent in vitro fertilisation
and experienced venous thromboembolismwas 4.2/1000 (n=99)
comparedwith 2.5/1000 (n=291) of the 116 960matchedwomen
(table 2⇓). The risk after in vitro fertilisation increased during
the whole pregnancy (P<0.001; hazard ratio 1.77, 95%
confidence interval 1.41 to 2.23) and differed between the
trimesters (P=0.002, fig 1⇓ and table 3⇓). In particular the risk
was increased during the first trimester (1.5/1000 v 0.3/1000,
hazard ratio 4.05, 2.54 to 6.46). The risk did not differ between
the two groups of women before pregnancy (hazard ratio 0.85,
0.66 to 1.10) and during the year after delivery (1.29, 0.82 to
2.02, table 2).
Pulmonary embolism occurred in 19 women who underwent in
vitro fertilisation (8.1/10 000) compared with 70 of the 116 960
matched women (6.0/10 000). The risk was increased after in
vitro fertilisation (P<0.0034; hazard ratio 1.42, 0.86 to 2.36, fig
2⇓ and table 4⇓) and differed between the trimesters (P=0.0092).
In particular the risk was increased during the first trimester
(3.0/10 000 v 0.4/10 000, 6.97, 2.21 to 21.96).
Figure 3⇓ shows the time trend of diagnoses. The incidence of
venous thromboembolism during pregnancy in womenwho did
not undergo in vitro fertilisation was comparable to that of
women in Sweden and Norway during the 1990s.5 6 However,
the incidence increased during the first decade of the new
millennium, although it seemedmainly confined to outpatients.
No significant interaction was observed between body mass
index and in vitro fertilisation on incidence of venous
thromboembolism (P=0.21). The incidence in women who did
not undergo in vitro fertilisation, however, increased as expected
by bodymass index (P<0.001), but no such effect was observed
in women after in vitro fertilisation (P=0.46, fig 4⇓).
Further multivariate analysis taking calendar period, parity,
single or multiple births, smoking, education, maternal age,
country of birth, and marital status into account was carried out
stratified on bodymass index in two categories: <25 and 25-29.9
(table 5⇓). Adjustment did not alter the significance of the main
finding. The adjusted hazard ratio of venous thromboembolism
during the first trimester was 4.22 (95% confidence interval
2.46 to 7.26). Multiple births seemed to have an influence on
incidence of venous thromboembolism (adjusted hazard ratio
2.12, 1.38 to 3.28).
A separate multivariate analysis on women with first births after
in vitro fertilisation compared with women not requiring assisted
reproduction resulted in a hazard ratio of 1.64 (1.23 to 2.18)
during the whole pregnancy and 3.50 (1.81 to 6.80) during the
first trimester. The overall risk during 2001-08 compared with
1990-2001 did not decrease (table 5).
Discussion
Pregnant women are at higher risk of venous thromboembolism
after in vitro fertilisation, particularly during the first trimester.
The risk of pulmonary embolism in women after in vitro
fertilisation was increased almost sevenfold during the first
trimester, although the absolute risk was low (2-3 additional
cases of pulmonary embolism per 10 000 pregnancies).
Pulmonary embolism is, however, an elusive condition that is
difficult to diagnose and is a leading cause of maternal death.11 12
Our finding is therefore important to health professionals dealing
with womenwho are recently pregnant after in vitro fertilisation.
Themedical literature contains numerous case reports of venous
thromboembolism during pregnancies after in vitro fertilisation,
and these articles have been reviewed repeatedly.7 9 16 One reason
why these case reports attract attention is the unusual sites of
the thromboses, such as the arms or neck. These reviews
concluded that the risk of venous thromboembolism after in
vitro fertilisation is comparable to that of pregnancies after
natural conception,9 different to our findings. In our study the
incidence of venous thromboembolism in women after in vitro
fertilisation significantly increased during the whole pregnancy
and differed between the trimesters, in particular during the first
trimester. This finding in the first trimester is in line with a
recently published study.10 However, the risk estimate in that
study was almost double that of the present study—around
10-fold compared with fivefold. This difference in risk estimates
probably resulted from the absence of matching by calendar
period. From the Swedish medical birth register we matched
each woman who had undergone in vitro fertilisation with five
women who had not by both calendar period and age. Matching
by age is important as women with pregnancies after in vitro
fertilisation are on average older than those with natural
pregnancies.10 It is well known that the incidence of
thromboembolism increases with age.17 We also matched by
calendar year of delivery, which avoided biased estimates as
the number of pregnancies after in vitro fertilisation and the
number of thromboembolic events both increase by calendar
year. The in vitro fertilisation procedure has changed over time
with the introduction of more patient friendly protocols, less
vigorous stimulation with lower doses of gonadotropins and,
particularly in Sweden, a decreasing rate of multiple births, from
almost 30% to 5%.15 Adjustments were also needed to take
account of the increased incidence of venous thromboembolism
noted recently.10 We analysed and adjusted for several maternal
factors known to affect pregnancy and vascular disease outcome
such as age, calendar year of delivery, body mass index, parity,
smoking, country of birth, marital status, and education. The
risk of venous thromboembolism increased by bodymass index
in women who did not undergo in vitro fertilisation but not in
those who did (fig 4). The reason for this could not be explained.
It could be speculated that differing oestrogen levels in lean and
obese women might play a part. Furthermore, the ovarian
hyperstimulation syndrome is more common in women with a
low body mass index.18 19 Since the ovarian hyperstimulation
syndrome is closely related to venous thromboembolism this
might also play a part.
Strengths and limitations of this study
The patient register is generally considered to have high validity
and was used to estimate the incidence of venous
thromboembolism in pregnant women during 1990-93.4 13 In
the present study we found a similar incidence in women who
did not undergo in vitro fertilisation during that period.
However, thromboembolic events in women regardless of
whether they underwent in vitro fertilisation increased during
the first decade of the newmillennium. One reason for this could
be the inclusion of outpatient diagnoses (fig 3). In addition,
awareness of venous thromboembolism during pregnancy has
increased over time. A high baseline index for suspicion of
venous thromboembolism during pregnancy is critical for
diagnosis because many of the clinical signs and symptoms are
also common in normal pregnancies.20 21 Improvement in
diagnostic procedures, including a more extensive use of
ultrasound examinations, has probably contributed to the
increased incidence of venous thromboembolism.20 22 23 We have
no information on the severity of the venous thromboembolic
events. Furthermore, improvements in diagnostic procedures
and increased doctors’ awareness could contribute to the
increased incidence of venous thromboembolism.24 A limitation
of our study is that owing to a lack of relevant data we could
not check these assumptions.
A further limitation is that we cannot rule out surveillance bias
(detection bias) between the two groups of women. Surveillance
bias is unlikely, however, because of the noticeable significant
increase of thromboembolic events during the first trimester in
pregnancies after in vitro fertilisation. A further argument
against surveillance bias was the absence of an increased risk
after delivery.
A weakness of the Swedish medical birth register is that it only
includes women with deliveries. Thus an obvious bias is that
more complicated pregnancies resulting in fatal outcomes to
the mothers were not included. This could underestimate the
true risk of venous thromboembolism and, in particular,
pulmonary embolism during a pregnancy after in vitro
fertilisation. Notably a major cause of maternal deaths during
pregnancy is embolism.11 12 Furthermore, the use of matched
controls in the present study clearly indicated an increased risk
of thromboembolism after in vitro fertilisation.
A further potential weakness could be an influence of parity on
the propensity to acquire thromboses. However, this is opposed
by the fact that also women with first births had an increased
risk of venous thromboembolism compared with natural
pregnancy. Another bias could be the presence of thrombophilia
and the antiphospholipid syndrome as these might influence
fertility.25 26
Time distribution of thromboembolic events
The distribution of pulmonary embolism and venous
thromboembolism during the three trimesters after in vitro
fertilisation (figs 1 and 2⇓) contrasted with that of natural
pregnancies.17 Notably, the risk of pulmonary embolism in
natural pregnancies is highest in the postpartum period,17 20 27
whereas in the present study the greatest risk in women after in
vitro fertilisation was during the first trimester. The close time
relation to the in vitro fertilisation procedure suggests that
changes induced by the procedure itself could be of
pathophysiological importance. A plausible initiator of adverse
mechanisms could be the noticeable increase in endogenous
oestrogen levels during the stimulation phase of treatment before
the actual procedure.7 During in vitro fertilisation the oestrogen
level increases rapidly (10-fold to 100-fold) from the
down-regulation phase to the stimulation phase.28 Exogenous
oestrogens have been repeatedly associated with an increased
incidence of venous thromboembolism, irrespective of the
indication for their use. The first reports were in women using
oral contraceptives containing oestrogen and recently in women
using oestrogen after the menopause.29-31 In the largest
randomised study to date the risk of venous thromboembolism
in women using exogenous oestrogens compared with placebo
was doubled (hazard ratio 2.06, 95% confidence interval 1.57
to 2.70).31 An increased risk of cardiovascular events has also
been shown in men receiving oestrogen for testosterone
dependent prostatic carcinoma.32
Conclusions
Our results show an increased risk of thromboembolism and,
importantly, pulmonary embolism in pregnant women after in
vitro fertilisation. Doctors should be aware of these increased
risks because the symptoms of pulmonary embolism can be
insidious and the condition is potentially fatal. Efforts should
focus on the identification of women at risk of
thromboembolism, with prophylactic anticoagulation considered
in women planning to undergo in vitro fertilisation.
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What is already known on this topic
Embolism is an important cause of maternal mortality in developed countries
In vitro fertilisation (IVF) is increasingly used for assisted reproduction
Reports suggest that the risk of venous thromboembolism is not increased after IVF compared with natural pregnancies although a
recent report showed an increased risk during the first trimester
What this study adds
The risk of venous thromboembolism increased during all trimesters in women after IVF, in particular during the first trimester
The risk of pulmonary embolism significantly increased during the first trimester
Tables
Table 1| Characteristics of pregnant women who underwent in vitro fertilisation (IVF) and women with natural pregnancies between 1990
and 2008, Sweden. Values are numbers (percentages) unless stated otherwise
Natural pregnancies (n=116 960)IVF pregnancies (n=23 498)Characteristics
Maternal age at birth:
1510 (1.3)322 (1.4)19-24
18 438 (15.8)3764 (16.0)25-29
50 575 (43.2)10 129 (43.1)30-34
40 083 (34.3)8016 (34.1)35-39
6354 (5.4)1267 (5.4)40-47
33.4 (3.9)33.3 (4.0)Mean (SD) age (years)
33 (31-36)33 (31-36)Median (interquartile range) age (years)
95 180 (81.4)20 267 (86.2)Born in Sweden
Prepregnancy body mass index:
20 228 (17.3)3961 (16.9)Missing data
62 464 (53.4)12 490 (53.2)<25
24 646 (21.1)5136 (21.9)25-29
9622 (8.2)1911 (8.1)≥30
Cigarette smoker:
7731 (6.6)1793 (7.6)Missing data
96 996 (82.9)20 130 (85.7)No
12 233 (10.5)1575 (6.7)Yes
Education (years):
1027 (0.9)48 (0.2)Missing data
11 741 (10.0)1789 (7.6)≤9
50 527 (43.2)10 588 (45.1)10-12
53 665 (45.9)11 073 (47.1)>12
Marital status:
7798 (6.7)1800 (7.7)Missing data
103 882 (88.8)21 569 (91.8)Married to or cohabiting with father of child
3,166 (2.7)51 (0.2)Single
2114 (1.8)78 (0.3)Other
Table 2| Venous thromboembolism and pulmonary embolism events in pregnant women after in vitro fertilisation (IVF) and women with
natural pregnancies matched on age and calendar period of delivery. Values are numbers (percentages) of women unless stated otherwise
Proportional hazard regression (95% CI)Natural pregnancies (n=116 960)IVF pregnancies (n=23 498)Events in relation to pregnancy
Venous thromboembolism:
0.85 (0.66 to 1.10)415 (0.35)71 (0.30)Prepregnancy
1.77 (1.41 to 2.23)291 (0.25)99 (0.42)Pregnancy and delivery
1.29 (0.82 to 2.02)95 (0.08)24 (0.10)Days 43-365 postpartum
Pulmonary embolism:
1.04 (0.65 to 1.66)103 (0.09)21 (0.09)Prepregnancy
1.42 (0.86 to 2.36)70 (0.06)19 (0.08)Pregnancy and delivery
0.60 (0.18 to 1.98)26 (0.02)3 (0.01)Days 43-365 days postpartum
Table 3| Time to first venous thromboembolic event by trimester in pregnant women after in vitro fertilisation (IVF) and women with natural
pregnancies matched on age and calendar period of delivery. Effect of different levels of effect modifier body mass index (BMI) is also
given. Values are numbers (percentages) of women unless stated otherwise
Proportional hazard regression (95% CI)*
Hazard ratio
(95% CI)
Natural
pregnancies
(n=116 960)
IVF
pregnancies
(n=23 498)Variables BMI >30BMI 25-29.9BMI <25Total
1.01 (0.22 to 4.6)2.61 (0.97 to 7.07)6.64 (3.6 to 12.23)4.05 (2.54 to 6.46)4.61 (2.95 to 7.21)38 (0.03)36 (0.15)First trimester (weeks 1-12)
—†2.13 (0.66 to 6.93)1.04 (0.40 to 2.72)1.11 (0.54 to 2.29)1.00 (0.51 to 1.97)63 (0.05)23 (0.10)Second trimester (weeks
13-25)
0.26 (0.04 to 1.91)1.80 (0.81 to 4.01)1.30 (0.61 to 2.80)1.30 (0.77 to 2.19)1.04 (0.64 to 1.69)94 (0.08)33 (0.14)Third trimester (week 26 to
<3 days before birth)
1.45 (0.49 to 4.27)1.55 (0.75 to 3.24)1.66 (0.90 to 3.05)1.59 (1.03 to 2.45)1.69 (1.15 to 2.48)192 (0.16)49 (0.21)≤3 days before to 42 days
after birth
0.530.07<0.001<0.001———P value for test of
difference‡
0.330.860.00060.002———P value for test of equal
effect in all time periods§
*Women with complete data on BMI.
†Weeks 13-25 are merged with week 26 until three days before delivery owing to few events.
‡Wald χ2 test for difference between IVF and no IVF.
§Wald χ2.
Table 4| Time to first event of pulmonary embolism during trimesters in pregnant women after in vitro fertilisation (IVF) and women with
natural pregnancies matched on age and calendar period of delivery. Values are numbers (percentages) unless stated otherwise
Proportional hazard regression (95% CI)Natural pregnancies (n=116 960)IVF pregnancies (n=23 498)Variables
6.97 (2.21 to 21.96)5 (0.004)7 (0.03)First trimester (weeks 1-12)
0.42 (0.05 to 3.20)13 (0.01)5 (0.02)Second trimester (weeks 13-25)
0.40 (0.10 to 1.68)18 (0.02)6 (0.03)Third trimester (week 26 to <3 days before birth)
1.79 (0.86 to 3.74)49 (0.04)11 (0.05)≤3 days before to 42 days after birth
0.0034——P value for test of difference*
0.0092——Test of equal effect in all time periods†
*Wald χ2 for difference between IVF and no IVF.
†Wald χ2 test.
Table 5| Multivariate analysis stratified on body mass index (BMI) in pregnant women with BMI <30: 23 498 women after in vitro fertilisation
(IVF) and 116 960 women with natural pregnancies matched on age and calendar period of delivery
Hazard ratio (95 % CI)
Variables Adjusted by conditioning on BMIBMI 25-29.9BMI <25
1=reference1=reference1=referenceNatural pregnancies
IVF pregnancies:
4.13 (2.37 to 7.17)2.40 (0.85 to 6.80)5.21 (2.68 to 10.14)First trimester (weeks 1-12)
1.18 (0.55 to 2.51)1.78 (0.53 to 5.93)0.91 (0.34 to 2.46)Second trimester (weeks 13-25)
1.25 (0.69 to 2.25)1.38 (0.57 to 3.33)1.17 (0.53 to 2.58)Third trimester (week 26 to <3 days before birth)
1.16 (0.69 to 1.93)1.27 (0.59 to 2.75)1.10 (0.56 to 2.17)≤3 days before to 42 days after birth
<0.0010.77<0.001P value for test of difference*
0.00170.420.001Test of equal effect in all time periods†
No of older siblings:
—1=reference1=referenceNone
0.83 (0.63 to 1.1)1.36 (0.58 to 3.19)0.92 (0.65 to 1.30)≥1
1=reference1=referenceSingle birth
2.06 (1.32 to 3.21)1.33 (0.57 to 3.13)2.52 (1.49 to 4.25)Multiple births
Smoking at start of pregnancy:
—1=reference1=referenceNo
0.89 (0.56 to 1.41)0.89 (0.45 to 1.77)0.91 (0.49 to 1.68)Yes
Education (years):
—1=reference1=reference≤9
0.88 (0.53 to 1.44)0.55 (0.27 to 1.12)1.16 (0.57 to 2.39)10-12
1.06 (0.64 to 1.75)0.80 (0.40 to 1.62)1.26 (0.61 to 2.59)>12
Maternal age at delivery (years):
—1=reference1=reference<35
≥35
1.14 (0.67 to 1.96)2.34 (0.85 to 6.45)0.84 (0.43 to 1.63)First trimester (weeks 1-12)
0.92 (0.48 to 1.75)2.25 (0.73 to 6.88)0.60(0.25 to 1.43)Second trimester (weeks 13-25)
0.84 (0.51 to 1.38)1.20 (0.58 to 2.49)0.60(0.30 to 1.23)Third trimester (week 26 to <3 before birth)
1.88 (1.26 to 2.78)2.64 (1.41 to 4.96)1.53 (0.91 to 2.57)≤3 before to 42 days after birth
Country of birth:
——1=referenceSweden
1.62 (1.09 to 2.41)3.06 (1.45 to 6.44)1.14 (0.72 to 1.83)Other country
Calendar period:
1=reference1=reference1=reference1990-2001
1.86 (1.43 to 2.43)2.64 (1.64 to 4.25)1.55 (1.12 to 2.14)2002-08
Marital status:
1=reference1=reference1=referenceMarried to or cohabiting with father of child
1.03 (0.52 to 2.03)1.34 (0.53 to 3.36)0.81 (0.29 to 2.21)Other
*Wald χ2 for difference between IVF and no IVF.
†Wald χ2.
Figures
Fig 1 Proportional hazard regression of venous thromboembolism in pregnant women after in vitro fertilisation (n=23 498)
and in women with natural pregnancies (n=11 960) matched on age and calendar period of delivery
Fig 2 Proportional hazard regression of pulmonary embolism in pregnant women after in vitro fertilisation (n=23 498) and
in women with natural pregnancies (n=11 960) matched on age and calendar period of delivery
Fig 3 Time trends of incidence of registered venous thromboembolic (VTE) diagnoses per 1000 pregnant women after in
vitro fertilisation and women with natural pregnancies matched on age and calendar period of delivery in Swedish national
patient register, National Board of Health and Welfare
Fig 4 Proportional hazard regression of venous thromboembolism in three strata for body mass index (<25, 25-29.9, and
≥30) in pregnant women after in vitro fertilisation (n=23 498) and in women with natural pregnancies (n=116 960) matched
on age and calendar period of delivery

IV

Increased incidence of hypertension in women after IVF pregnancy: A population-based 
cohort study from Sweden. 
Eli Westerlund1, Lena Brandt2, Outi Hovatta3, Håkan Wallén1, Anders Ekbom2, Peter 
Henriksson1 
1Department of Clinical Sciences, Danderyd Hospital, 2Division of Epidemiology, 
Department of Medicine, 3Department of Clinical Science, Intervention and Technology, 
Karolinska University Hospital. 
Karolinska Institutet, Stockholm, Sweden 
 
Corresponding author: Eli Westerlund 
Division of Internal Medicine, Department of Clinical Sciences, Danderyd Hospital 
182 88 Stockholm, Sweden 
Phone: +46 709 938 278 
Fax: +46 8 755 58 61 
E-mail address: eli.westerlund@telia.com 
  
Abstract 
Objective: To investigate whether cardiovascular disease (CVD) and related risk factors have 
a higher incidence in women after IVF pregnancy as compared to women who delivered after 
natural conception. 
Design: A cohort study in Sweden of all women who had given birth to a child after in vitro 
fertilization (IVF) between 1990 and 2008 and individually matched women from the 
Swedish Medical Birth Register. Inpatient and outpatient diagnoses of CVD and related risk 
factors in both groups were identified by linkage to the Swedish National Patient Register. 
Participants: 23,498 women who had given birth to a child after IVF between 1990 and 2008 
and 116,960 individually matched women. 
Main outcome measures: Incidence rates of hypertension, diabetes, stroke and coronary 
heart disease in both groups. 
Results: After a mean follow-up of 8.6 years in both groups, the incidence rate of 
hypertension was 2.58/10.000 person-years (n=520) in the IVF group as compared to 
2.13/10.000 person-years (n=2129) in the control group. Multivariable analysis adjusted for 
women’s BMI, smoking, education and country of birth showed that hypertension had a 
higher incidence in IVF mothers [Hazard Ratio (HR) 1.27, 95% Confidence Interval (CI) 
1.13-1.41] as compared to mothers from the Medical Birth Register. There was a trend to a 
higher incidence of stroke (HR 1.27, 95% CI 0.96-1.68). However, the incidence of coronary 
heart disease and diabetes did not differ after IVF pregnancies as compared to controls (HR 
0.72, 95% CI 0.44-1.17 respectively HR 0.96, 95% CI 0.81-1.14). 
Conclusion: Hypertension was more prevalent after IVF pregnancies. This could indicate that 
infertile women could have a propensity to develop CVD later in life. 
Keywords:  Infertility, cardiovascular disease (CVD), In Vitro Fertilization (IVF), 
hypertension, stroke, diabetes 
 Introduction 
Infertility afflicts more than 10% of all couples worldwide (1). This condition has some 
relation to cardiovascular diseases (CVD). One is via the polycystic ovarian syndrome 
(PCOS), the most common cause of female infertility (2). Women with PCOS are 
characterized by a greater body mass and a sevenfold increased risk of myocardial infarction 
(3). Both obesity as well as underweight seems to be associated with reduced fertility (4). In 
addition, smoking, age and environmental factors also seem to impair the development and 
function of the reproductive organs, which could lead to hormonal imbalance and reduced 
fertility (5). 
Endothelial dysfunction is an early marker of CVD (6). Possible associations of endothelial 
dysfunction in the ovarian vasculature and infertility have to our knowledge not as yet been 
studied. However, endothelial dysfunction in PCOS has been found in both humans and in 
animal models (7, 8). In addition, women with PCOS have menstrual irregularities, which are 
associated with subfertility (9) and increased risk of CVD (10).  
Heart disease is the leading cause of death in women while stroke is the third most common 
cause of death (11).  
Thus, the aim of our study was to assess whether CVD and related risk factors have a higher 
incidence in women after IVF pregnancy as compared to women who delivered after natural 
conception.  
 
Methods: 
Data sources 
We performed a cohort study using linkage of Swedish population-based registers maintained 
at the Swedish National Board of Health and Welfare and Statistics Sweden (12, 13).   
Sweden has excellent conditions for observational studies in the health care area, with high-
quality population-based registers covering essentially all inpatient and now also outpatient 
care and birth records. Linking of the Swedish Medical Birth Register (MBR) and the 
Swedish IVF Register allowed us to compare the incidence of CVD after pregnancy in 
subjects who had undergone IVF to age and time period matched control women.  
Individual records were linked across the registers using the unique personal identity number 
assigned to all Swedish residents, i.e. individuals either born in Sweden or immigrating to 
Sweden (14).  
Information on women’s country of birth, pre-pregnancy body mass index (BMI), family 
situation, cigarette smoking habits, number of older siblings and singleton/multiple births was 
retrieved from the MBR. MBR was initiated in 1973 to give information on maternal, 
pregnancy and infant factors (12). Up to 1998, more than 98% of all births in Sweden were 
registered in the MBR. 
Women´s education was retrieved from the Register of Education, Statistics Sweden (15), by 
linkage through the personal identity number (14).  
Diagnoses of CVD and related risk factors were found by linkage to the Swedish Patient 
Register of the National Board of Health and Welfare. The register comprises dates of 
admission and discharge, and main diagnosis with up to seven contributing diagnoses.  
Inpatient care is recorded nationwide since 1987. Outpatient visits at specialist clinics are 
included from 2000. Diagnoses were recorded according to the International Classification of 
Diagnoses (ICD), edition 9 (ICD-9) from 1990 to 1996 and edition 10 (ICD-10) from 1997 
onwards. 
The National Causes of Death Register contains data concerning immediate, contributory, and 
underlying causes of death classified using ICD-10. 
Study population 
All women undergoing successful IVF treatment between 1st of January 1990 and 31st of 
December 2008 were included. Each IVF woman was matched with up to five women from 
the MBR by calendar year of delivery ±2 years and maternal age ±1 year.  
Mothers who had given birth to a child as a result of IVF were retrieved from the Swedish 
IVF Register, which is now a part of the Swedish MBR at the National Board of Health and 
Welfare and includes information on IVF pregnancies since 1982. The MBR includes 
prospectively collected and validated information from pregnancy, delivery, and neonatal 
period on more than 99% of all births in Sweden since 1973.  
We restricted the retrieval to mothers of a child born as from 1990 and who had their first 
child born after assisted reproduction by IVF.  Thus, we identified 23 498 women who had 
given birth to a child after IVF during the time period 1990-2008 and 116,960 individually 
matched women. 
Follow-up and outcomes 
Follow-up started at the time of delivery. End of follow-up was 31st of December 2009 or the 
date of first registered event of the following: a CVD diagnosis (coronary heart disease or 
stroke) or a diagnosis of a related risk factor (hypertension and diabetes), emigration from 
Sweden, or death. 
Hypertension was defined as ICD-9 codes 401-405, 642A-D and 642X, ICD-10 codes I10-13, 
I15, O10.0-4, O11.9, O13.9 and O16.9. Diabetes was defined as ICD-9 codes 250 and 648A 
and ICD-10 codes E10-11, E14 and O24. Codes that specifically differentiated between type 1 
and type 2 diabetes were introduced first with ICD-10 in 1997. 
Coronary heart disease was defined as unstable angina (ICD-9 code 411B, ICD-10 code 
I20.0), or myocardial infarction (ICD-9 codes 410 and 412, ICD-10 codes I21-23 and I25.2). 
Stroke comprised cerebral infarction (ICD-9 codes 433-434 and 438, ICD-10 codes I63 and 
I69.3-4) or intracerebral haemorrhage (ICD-9 code 431, ICD-10 code I61). The positive 
predictive values (i.e. validity) of myocardial infarction  and stroke diagnoses in the Swedish 
hospital discharge register have been demonstrated to be around 95% when only primary 
diagnoses are considered (16, 17). 
Hypothyroidism was defined as ICD-9 codes 243-44 and ICD-10 codes E02.9 and E03, 
whereas we used ICD-9 codes 642.4-7 and ICD-10 code O14 for preeclampsia. Polycystic 
ovarian syndrome was defined as ICD-9 code 256.4 and ICD-10 code E28.2. 
The study was approved by the Research Ethics Committee of Karolinska Institutet, 
Stockholm, Sweden (Dnr 2010/267-31/4). 
 
Statistical analysis: 
Baseline variables and population characteristics are presented as means and standard 
deviations for normally distributed variables and as number and frequencies for categorical 
variables. BMI, educational level, smoking, country of birth, hypertension, diabetes, coronary 
heart disease and stroke were all analyzed as categorical variables. 
The person-time for each woman was calculated from end of pregnancy to the month of 
diagnosis of the end-point (CVD or related risk factors), the month of death from other 
causes, emigration or end of follow-up (31st of December 2009). 
We investigated the incidence of hypertension, diabetes, stroke and coronary heart disease in 
both univariable and in multivariable-adjusted analysis models. As the IVF group differed 
from the control group concerning educational level, smoking habits and country of birth, 
multivariable analyses were performed adjusting for those background factors and in addition  
BMI. Hazard ratios (HR) and 95% Confidence Intervals (95% CI) were estimated using 
proportional hazard regression analysis.   
All statistical calculations were performed using the SAS software package, version 9.2, by 
SAS Institute Inc., Cary, NC, USA.  
 
Results: 
The baseline characteristics of the study sample of women having their first delivery from 
1990 to 2008 are given in table 1. The mean age of the women in the IVF group was 33.3 ± 
4.0 respectively 33.4 ± 3.9 in the control group. Women in the IVF group had a higher 
educational level, were in a less frequency smokers and had a higher proportion of women 
who were born in Sweden as compared to the control group.   
As shown in table 2, only a few women emigrated and just 0.5% died during follow-up. The 
mean follow-up time was 8.6 ± 4.6 years contributing to 201 498 person-years at risk in the 
IVF group and a follow-up of 8.6 ± 4.9 with 1 000 368 person-years at risk in the control 
group. 
During this period, 823 women developed a first event (diabetes, n = 201; hypertension, n = 
520; coronary heart disease, n = 23; stroke, n = 79). According to table 3, the proportion of 
women with hypertension and stroke was slightly greater in the IVF group as compared to the 
MBR controls. 
Multivariable analysis adjusted for women’s BMI, smoking habits, education and country of 
birth identified a higher incidence of hypertension among IVF women (HR 1.27, 95% CI 
1.13-1.41) as compared to MBR controls. There was a trend to a higher incidence of stroke 
(HR 1.27, 95% CI 0.96-1.68) but the incidence of coronary heart disease and diabetes did not 
differ after IVF pregnancies as compared to controls (HR 0.72, 95% CI 0.44-1.17 and HR 
0.96, 95% CI 0.81-1.14).  
As shown in table 4, when looking at the whole group of women, those who were smoking 
more than 10 cigarettes daily had a higher incidence of coronary heart disease as compared to 
non-smokers (HR 5.46, 95% CI 3.55-8.40). Even women smoking less than 10 cigarettes 
daily had a higher incidence of coronary heart disease as compared to non-smokers (HR 4.16, 
95% CI 2.81-6.18). Furthermore, as expected, an increase in BMI resulted in a higher 
occurrence of CVD. BMI more than 30 increased the incidence of diabetes (HR 5.25, 95% CI 
3.09-7.07), coronary heart disease (HR 5.23, 95% CI 2.34-11.72) and hypertension (HR 3.84, 
95% CI 3.07-4.82), whereas stroke occurrence was unaffected (HR 1.15, 95% CI 0.70-1.90). 
 The results of all univariable and multivariable analyses are shown in table 4. 
 
Discussion: 
The main result of this large, population based cohort study is a higher incidence of 
hypertension in women who had a child born after IVF than in women who delivered after 
natural conception in this Swedish population during the time period 1990-2008. IVF mothers 
also had a trend to a higher incidence of stroke, while the incidence of coronary heart disease 
and diabetes did not differ between the two groups of women. 
To our knowledge, this is the first prospective cohort study investigating whether CVD and 
related risk factors have a higher incidence in women after IVF pregnancy as compared to 
women who delivered after natural conception. 
The main advantages of this study are its sample size and its prospective nature. To get a 
representative group of controls we included five control women for each IVF woman and 
were able to retrieve data about smoking, BMI, country of birth and education by matching of 
relevant registers.  
Women in the IVF group seemed to have life circumstances that should reduce the risk of 
CVD. This could be exemplified by a lower frequency of smokers, a higher educational level 
and a lower proportion of women born abroad. 
However, IVF women had a higher incidence of hypertension than control women. 
Hypertension is a main risk factor for CVD but there is a long-term delay between the 
initiation of vascular disease processes and manifest vascular diseases such as coronary heart 
disease and stroke (18). 
The number of events with coronary heart disease (n=23) and stroke (n=79) in the 23.498 
women in the IVF group was small. However, when looking at the effects of the risk factors 
in the whole group of women (Table 4), we found as expected that obese women (BMI>30) 
had a higher incidence of diabetes, coronary heart disease and hypertension. 
 We suggest that the number of women, the mean age and follow-up time in the present study 
were too low and the mean follow up period of 8.6 years too short to have a high enough 
cardiovascular event rate to reach statistical power. Due to increasing numbers of IVF-treated 
women, most of the included women had their IVF treatment after year 2000. As the mean 
age during inclusion was 33 years, the mean age at end of follow- up was only 41 years. 
Despite this low mean age, when stratifying the whole group into different subgroups of 
smoking, those who were smoking more than 10 cigarettes daily had an increased incidence 
of coronary heart disease as compared to non-smokers. Cigarette smoking is associated with a 
two year earlier onset of menopause (19) and smoking is an important determinant for 
coronary heart disease in women (20, 21). 
The result of our study is in accord with the study of Parikh et al, which was conducted in 
Swedish women with self-reported data on subfertility in the Swedish MBR (22). They 
compared women reporting more than 5 years of subfertility with women who got pregnant 
within one year and found a significantly higher risk of CVD among subfertile women with a 
HR of 1.19 (95% CI 1.02-1.39). In contrast to Parikh, we separated the different subgroups of 
CVD and related risk factors into hypertension, diabetes, coronary heart disease and stroke. 
The strength of our study is thus the more specific diagnose codes. In the subgroup of stroke 
diagnoses we excluded subarachnoidal bleedings and subdural haematomas to get a more 
distinct group which is also related to hypertension as a risk factor. 
As in previous reports, preeclampsia was overrepresented in the IVF group, and the condition 
is a well known risk factor for development of CVD later in life (23, 24). Actually, the risk is 
more than doubled as compared to those with uncomplicated pregnancy (25). Preeclampsia 
occurs in 3-5% of normal pregnancies, and in our IVF group there were 7.0% with 
preeclampsia as compared to 5.2% in the control group. 
The incidence of hypertension could be higher in women after oocyte donation (26), but as 
this procedure was not allowed in Sweden until 2003 only a very low proportion in the IVF 
group had oocyte donation in the present study.  
PCOS, prevalent in 6-8% of women in reproductive ages (27), accounts for up to 15% of 
women with female infertility and is associated with subclinical atherosclerosis as assessed by 
carotid intima-media thickness and endothelial dysfunction (28). The number of women with 
PCOS was higher in the IVF group than in the control group, but the proportion was low in 
both groups. We speculate whether this condition was under-reported. 
Excess adiposity as assessed by BMI is associated with subfertility (29) and incident CVD 
(30). However, adjustment for BMI neither nullified nor attenuated our CVD estimates, 
suggesting that factors other than BMI underlie the increased incidence of hypertension in the 
IVF group. 
Another possible mechanistic link between infertility and CVD is hypothyroidism, which is 
linked both to infertility (31) and incident CVD (32). However, in our material, the prevalence 
of women with hypothyroidism was low in both the study and control group. Therefore, we 
assume that this condition did not affect the result. 
Limitations: 
Our data are based on results from a register study. Therefore, it is not possible to determine 
causality from our results, and it is still plausible that increased blood pressure and infertility 
occur concomitantly, rather than one preceding the other. 
 
Only women giving birth to a baby after IVF treatment are included in the IVF register. To 
get a complete picture of the situation, all women doing IVF treatments should preferably be 
included. This is today not possible with available registers. 
Unfortunately, we have no information about causes of infertility in our women in the 
register. In a recent report 64% were due to female factors and male factors accounted for just 
19% in all infertile couples. The remaining 17% had an unknown cause (33). In our study 
material with more than 20.000 IVF women, male infertility cases may have diluted the 
results causing an underestimation of the true difference. 
Diagnoses of hyperlipidaemia and cholesterol levels are not included in our cohort study. 
Hyperlipidaemia diagnoses codes are not so well recorded in registers in general and has thus 
a low validity. Cholesterol levels are not at all included in the registers. This is of course a 
limitation of the study since hypercholesterolaemia is a major CVD risk factor (34). 
Differences in cholesterol levels between the two groups could have affected the results of the 
study. As the women in the IVF group could have a lowered risk of CVD due to beneficial 
life circumstances this could well be true concerning lipid levels. Two other possible 
confounders in this study could be physical activity and alcohol intake, as both could 
influence the risk of CVD.  
Certainly, some of the study subjects used hormone replacement therapy (HRT) to prevent 
postmenopausal symptoms during the follow-up period. There are a lot of conflicting reports 
regarding HRT and CVD risk (35, 36). However, a mean age of 41 years at follow-up is well 
below the mean age of menopause in Sweden. Thus HRT should possibly not have affected 
our results.  
Conclusion: 
Our results show that IVF pregnancy is associated with a higher incidence of hypertension in 
the years after delivery as compared to delivery after natural conception. This could indicate 
that infertile women might be prone to develop CVD later in life. The trend to a higher 
incidence of stroke seems to support such a contention. However, the incidence of manifest 
CVD is low in women at the present age distribution.  
A longer follow-up of an IVF cohort in the future could give us a final answer.  
Meanwhile, we recommend clinicians to pay a close attention to and measure blood pressure 
in women who have passed an IVF treatment as they seem to have a higher propensity to 
develop hypertension. These women should be offered antihypertensive treatment if blood 
pressure increases above reference levels in order to prevent vascular damage. 
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Table 1. Characteristics of women from IVF register and Medical Birth Register (MBR) 
during the time period 1990–2008. 
   Women from  IVF register  Women from MBR 
Total number  n=23,498 n=116,960 
Mothers age at birth of the child (years)  
19‐24  1.4% 1.3% 
25‐29  16.0% 15.8% 
30‐34  43.1% 43.2% 
35‐39  34.1% 34.3% 
40‐47  5.4% 5.4% 
Mean age (±SD)  33.3 (±4.0)  33.4 (±3.9) 
Median age (quartiles) 33 (31;36) 33 (31;36) 
Mothers born in Sweden  86.2% 81.4% 
Prepregnancy  Body Mass Index (BMI)  
Missing  16.9% 17.3% 
<25  53.2% 53.4% 
 25‐29  21.9% 21.1% 
 ≥30  8.1% 8.2% 
Cigarette smoker   
Missing  7.6% 6.6% 
No  85.7% 82.9% 
<10 cigarettes/day  4.9% 6.7% 
≥10 cigarettes/day  1.8% 3.8% 
Education (years)   
Missing  0.2% 0.9% 
≤9  7.6% 10.0% 
10‐12  45.1% 43.2% 
>12   47.1% 45.9% 
Single/multiple birth  
Single birth  83.1% 97.4% 
Multiple birth  16.9% 2.6% 
Polycystic ovarian syndrome, n (%)  788 (3.4%) 563 (0.5%) 
Preeclampsia, n (%)  1646 (7.0%) 6117 (5.2%) 
Hypothyroidism, n (%) 447 (1.9%) 1790 (1.5%) 
 
 
Table 2. Follow-up time and drop-out frequency of the women in the study. 
  IVF women  Control women  
Total number (n) 23 498 116 960  
                   n           % n %
Possible to follow until end of follow-up 22 911 97.5 113 158 96.8
Emigrated 471 2.0 3 215 2.8
Deceased 116 0.5 587 0.5
   
Total years of follow-up 201 948 1 000 368  
Mean follow-up in years(±SD) 8.6 (±4.6)      8.6 (±4.9)  
 
 
Table 3. Total number and incidence per 10.000 person-years of diabetes, hypertension, 
coronary heart disease and stroke in IVF women and control women from the Medical 
Birth Register 1990-2008. 
  
      IVF women    Control women  
    n Incidence 95% CI n Incidence  95% CI 
  23498 
per 10.000  
person-years   116960
per 10.000 
person-years   
Diabetes   201 9.95 8.65-11.4 1 111 11.1 10.47-11.77
Hypertension 520 2.58 2.36-2.80 2 129 2.13 2.04-2.22 
Coronary heart disease 23 1.14 0.74-1.68 185 1.85 1.60-2.13 
Stroke  79 3.91 3.12-4.85 319 3.19 2.85-3.55 
Total  823 4.08 3.80-4.36 3744 3.74 3.62-3.86 
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per 10.000  
person-years   116960
per 10.000 
person-years   
Diabetes   201 9.95 8.65-11.4 1 111 11.1 10.47-11.77
Hypertension 520 2.58 2.36-2.80 2 129 2.13 2.04-2.22 
Coronary heart disease 23 1.14 0.74-1.68 185 1.85 1.60-2.13 
Stroke  79 3.91 3.12-4.85 319 3.19 2.85-3.55 
Total  823 4.08 3.80-4.36 3744 3.74 3.62-3.86 
Table 4. Cardiovascular disease Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
among Swedish women giving their first birth from 1990 to 2008 with additional adjustments 
for BMI, smoking, country of birth and educational level. 
 
      Diabetes Hypertension 
Coronary  
heart disease Stroke  
      HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Univariable analysis   
MBR group      1=reference 
IVF group 0.90 (0.77-1.05) 1.24 (1.13-1.37) 0.65 (0.42-1.00) 1.24 (0.97-1.58) 
Univariable analysis 
with exclusion^ 
MBR group      1=reference 
IVF group   0.90 (0.76-1.07) 1.26 (1.13-1.41) 0.64 (0.39-1.05) 1.22 (0.92-1.61) 
Multivariable analysis* 
MBR group 1=reference 
IVF group 0.96 (0.81-1.14) 1.27 (1.13-1.41) 0.72 (0.44-1.17) 1.27 (0.96-1.68) 
Country of birth 
Sweden 1=reference 
Other 2.14 (1.86-2.46) 0.99 (0.87-1.11) 1.21 (0.81-1.80) 1.40 (1.05-1.87) 
BMI before pregnancy 
<20 1=reference 
20-24.9 1.00 (0.75-1.35) 1.39 (1.13-1.72) 1.46 (0.67-3.20) 0.89 (0.59-1.32) 
25-29.9 2.02 (1.50-2.72) 2.23 (1.8-2.77) 2.37 (1.07-5.25) 1.07 (0.70-1.64) 
>30 5.25 (3.09-7.07) 3.84 (3.07-4.82) 5.23 (2.34-11.72) 1.15 (0.70-1.90) 
Smoking 
No 1=reference 
<10 cigarettes/day 0.88 (0.69-1.11) 1.06 (0.90-1.25) 4.16 (2.81-6.18) 1.12 (0.74-1.70) 
≥10 cigarettes/day 1.31 (1.02-1.68) 1.25 (1.03-1.53) 5.46 (3.55-8.40) 1.83 (1.18-2.83) 
Education 
Primary school 1.37 (1.15-1.62) 1.10 (0.95-1.28) 1.48 (1.00-2.21) 1.43 (0.8-2.58) 
High school 1=reference 
More than 12 years   0.79 (0.68-0.91) 1.10 (1.00-1.21) 0.95 (0.64-1.42) 1.08 (0.85-1.37) 
 
^ Univariable analysis with exclusion of women lacking information on smoking and BMI. 
* Multivariable analysis with additional adjustment for BMI, smoking, country of birth and educational 
level. 
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